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Historical perspective  
The genus Acinetobacter has endured numerous taxonomic changes since three decades. The history of 
this genus dates back to 1911 and isolated from soil by enrichment with calcium-acetate containing 
minimal media [1]. It was then described as Micrococcus colcoaceticus by Dutch microbiologist 
Beijerinck. In subsequent years, similar organisms were assigned to 15 various genera including Mima 
polymorpha, Moraxella lwoffii, Achromobacter, Bacterium anitratum, Alcaligenes, and Alcaligenes 
haemolysans. Current designation of Acinetobacter was proposed in 1954 by Brisou and Prevot and 
accepted in 1968, and then accepted in Bergey’s Manual of systematic Bacteriology in 1974 [2]. There 
are currently 32 known genotypes and the complex A.calcoaceticus-baumannii (ACB complex) includes 
four genotypes including A.baumannii, A.pittii, A.calcoaceticus and A.nosocomialis. Its most important 
representative, Acinetobacter baumannii, has appeared as one of the most burdensome pathogens for 
health-care establishments. It is clinical importance since 15 years has impelled, particularly  because of 
its capability of horizontally acquiring antimicrobial resistance and exhibiting multidrug resistance, 
sometimes pan-drug resistance and one of six important top-priority dangerous microorganisms [3]. 
Contrary to other Acinetobacter species which are usually isolated from soil and wet environment, 
A.baumannii found is hospital particularly from Intensive care units (ICU).  
Identification 
Acinetobacter baumannii is important opportunistic Gram negative, catalase positive, oxidase negative, 
non-motile, non-fermenting, opportunistic coccobacilli DNA G+C content of 39% to 47%. It grows well on 
solid media such as sheep blood agar or tryptic soy agar at 37°C for 24 hours [4]. The colony characters 
are smooth, occasionally muciod, grayish-white, and resembles those of Enterobacteriaceae colony 
diameter of 1.5 to 3 mm after overnight culture.  Sadly, no single metabolic test distinguishes 
Acinetobacter from other similar non-fermenting gram-negative bacteria. Of the few methods that have 
been validated for identification of Acinetobacter species, DNA-DNA hybridization remains the reference 
standard, however, it is too laborious to be implemented in routine microbiology laboratories. There are 
many molecular techniques developed and validated for identification such as amplified 16S rRNA gene 
restriction analysis [5], pulse-field gel electrophoresis [6],  repetitive extragenic palindromic sequence-based 
PCR  typing [7], randomly amplified polymorphic DNA typing [8],  restriction analysis of the 16S-23S rRNA 
intergenic spacer sequences [9], tRNA spacer fingerprinting [10], high-resolution fingerprint analysis by 
amplified fragment length polymorphism [11], sequence analysis of the 16S-23S rRNA gene spacer 
region [12], ribotyping, rpoB sequencing [13], multi loci sequences typing [14]. PFGE is still considered as 
golden techniques, however, laborious and time taking. ARDRA and AFLP analysis are accepted and 
validated reference methods, with large library profiles available and tRNA fingerprinting species 
identification but cannot discriminate between ACB complex. Other methods are but they are too 
laborious and also confined mainly to reference laboratories. Recently, whole genome sequencing [15], 
PCR-electrospray ionization mass spectrometry [16] and PCR of blaOXA-51-like [17] genes are used more 
commonly.  
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Epidemiology 
This pathogen is responsible for causing vast array of infections including soft-tissue infections, wound 
infections, blood-stream infections, ventilator-associated pneumonia, meningitis, urinary tract infections 
and mortality rates of approximately 30% [18]. Infections are more common in immunocompromised 
patients suffering from underlying diseases, undergoing treatment with broad-spectrum antibiotics, 
undergone major surgical intervention. Infections are associated precisely with prolonged 
hospitalization periods.  This pathogen can easily invade the body through intravascular catheters, open 
wounds and mechanical ventilators particularly in male gender and older age [17]. It is often very 
arduous to differentiate between A.baumannii colonization and infection [19]. There has been extensive 
dispute over infections caused by these isolates lead to adverse outcomes. A.baumannii is the cause of 
global outbreaks, exhibiting growing antimicrobial resistance. There are reports of multidrug resistance 
(MDR) from Europe, North-America, South-America, Asia-Pacific, Central-Asia and remote areas such as 
Tahiti in Pacific Ocean [20], [21], [22], [23], [24]. These MDR strains often cause epidemics in entire cities 
and countries [25], [26] and imported from high prevalence to historically low prevalence areas such as 
Spain to Norway [27]. A newly phenomenon has been viewed in which association of A.baumannii with 
infections subsequent to injuries in conflict, earthquake prone areas and war zones such as Turkey, Iraq 
and Afghanistan  [19], [28]. In addition, there has been several reports of heteroresistance and 
resistance against colistin throughout globe [29],[3].  The Spread of multidrug resistance A.baumannii 
epidemics caused by ‘European clones’ or better known as ‘international clones’ has been recorded 
throughout world [30]. International clones of A.baumannii I, II and III clone are not only confined within 
a city but also occurs on national scale, mostly through inter-hospital and international transfer [31].  
Antibiotic resistance  
The swift appearance of multi- and pandrug-resistant strains of Acinetobacter emphasizes the 
organism’s capacity to quickly adjust to selective differences in environmental pressures [32]. Resistance 
mechanisms in A. baumannii against beta-lactams are changes in penicillin-binding-proteins (PBPs) [33], 
alterations in porin proteins [34], over expression of efflux pumps [35] and hydrolysis by beta-lactmases. 
All genomic variants of A.baumannii contains non-inducible Chromosomal AmpC cephalosporinase and 
over expressed by presence of insertional sequence ISAba1 conferring resistance to extended spectrum 
cephalosporins [36]. Furthermore, A.baumannii also possess various classes of beta-lactamases such as 
class A extended-spectrum beta-lactamases [37], metallo-beta-lactamases (MBLs) [38] also bear 
intrinsically class D oxacillinase OXA-51-like group enzymes. It can acquire over 40 different variants 
class D oxacillinases conferring resistance to penicillins and carbapenems. The significant contribution of 
these enzymes to carbapenem resistance in A. baumannii has been highlighted, especially when they 
are assisted by ISAba1 and ISAba3 in the naturally occurring plasmid  [39].       
Treatment strategies  
When treatment is considered, there are very limited choices due to the resistance. Carbapenems are 
usually considered in susceptible isolates; however, since the rapid dissemination of carbapenem 
resistance, there has been a steep surge for other options. Resistance mechanism discussed above could 
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also be combined to results in high drug resistance, making selection of a pertinent empirical 
antimicrobial agent extremely arduous to function. Certainly, given the anticipation that                         A. 
baumannii would be most likely resistant to one of the common first line antibiotics, treatment should 
be performed following sound consideration of antimicrobial susceptibility testing. However, delay in 
the determining the appropriate treatment would lead to detrimental circumstances for the patient’s 
health. Lack of new treatment has resulted in using combination therapy such as combinations of 
sulbactam and carbapenems have been shown effective against isolates with carbapenem resistance 
[40]. There are several attempts been made in search of alternative therapies such as bacteriophage 
therapy, bactericidal gene transfer therapy, cathelicidins, radioimmuno-therapy, photodynamic-therapy, 
nevertheless, experimental developments are warranted for novel antimicrobial strategies for 
A.baumannii infections.   
Outline of thesis 
The aim of this thesis is Molecular characterization of multidrug resistant Acinetobacter baumannii 
causing nosocomial infections. Hereto, various aspects are addressed. In Chapter 2, outlined 
carbapenem resistant A. baumannii and investigated genetic diversity between local and international 
clones. In Chapter 3, we evaluated molecular methods for monitoring A.baumannii strains. Chapter 4, 
analysis was done in efficacy of doripenem & its combinations antimicrobial agents such as sulbactam, 
amikacin, colistin and tigecycline in experimental sepsis of carbapenem-resistant A.baumannii. In 
Chapter 5, global epidemiology colistin resistance was investigated; In Chapter 6 various issues in 
establishing molecular microbiology facility in developing countries were scrutinized. In Chapter 7, 
Challenges were observed in ICU-acquired infections caused by A.baumannii in developing countries. In 
Chapter 8, we collected a number of carbapenem resistant A.baumannii isolates from various 
collaborative hospitals of Turkey and Azerbaijan and compared with international clones. In Chapter 9, 
we analyzed efficacy of sulbactam & its combinations with imipenem, colistin & tigecycline in 
experimental model of carbapenem resistant A.baumannii sepsis.  
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The emergence of Carbapenem-resistant Acinetobacter baumannii is a threat to
modern medicine and has been recognised globally. Epidemic clones of A.baumannii are
associated with hospital epidemics throughout the world causing serious ramifications.
There are number of molecular typing techniques used for molecular characterisation,
however, due to lack of resources molecular epidemiology remains unfledged in developing
countries. In this study a total number of 205 carbapenem-resistant Acinetobacter species
were collected and compared with European Clone I, II and III. PCR for and blaOXA-51-like
was performed for confirmation and multiplex PCR was performed for blaOXA-23-like, blaOXA-
24-like and blaOXA-58-like genes. Isolates harbouring carbapenemases were selected for molecular
typing using PFGE, RAPD-PCR and REP-PCR and discriminatory index was performed.
The cost of all molecular typing methods was calculated. The blaOXA-51-like gene was present
in 188 (91.7%), and within these 188 isolates; blaOXA-23-like 36(19%), blaOXA-24-like 62(33%),
30(16%) carried blaOXA-58-like genes. PFGE typing revealed 13 clusters and 15 unique types,
RAPD-PCR, 11 clusters and 23 unique types and REP-PCR, 8 clusters and no unique types.
With 80% similarity cut-off value, 11 isolates were similar to EU clone I, 5 isolates were
similar to EU II and 3 isolates were similar to EU III. Cost of molecular methods was
compared between PFGE, RAPD-PCR and REP-PCR. PFGE was found to have high
discriminatory power and RAPD-PCR was economical.
Keywords: carbapenem; hospital infections; molecular typing.
In recent years, Acinetobacter
baumannii has emerged as a predominant cause
of healthcare-associated infections worldwide.
From an epidemiological point of view, its most
remarkable features as a nosocomial pathogen are
its ability to survive in the hospital environment
and to develop resistance to multiple antimicrobial
agents. It is responsible for various opportunistic
nosocomial infections including skin, wound and
urinary tract infections often targeting vulnerable
hospitalized patients1. In a recent European study
A.baumannii was among the eight most common
causes of nosocomial pneumonia and the second
most common pathogen in bloodstream infections
acquired in hospitals. Carbapenem resistance is
often mediated by OXA-carbapenemases-
encoding genes; extrinsically by bla
OXA-23-like
,
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bla
OXA-24-like
 and bla
OXA-58-like
, and intrinsically by
bla
OXA-51-like
 carbapenemases2. Outbreaks of this
organism in hospitals are frequently caused by
strains belonging to the European clones I-III.
Resistance to several antibiotics, in particular
carbapenems, is the hallmark of the most successful
clones3. Despite the widely accepted idea that a
few genotypic groups are responsible for a large
proportion of the burden of A. baumannii
infections, the genetic distinctness of clones
among themselves and from other genotypes
remains to be established.
Strain typing of A. baumannii has become
an indispensable epidemiological tool to identify
reservoirs and pattern of transmission. Pulsed-field
gel electrophoresis (PFGE), a macrogenomic strain
typing approach, is the most commonly employed
method in health care facilities.  However, PFGE
remains an expensive, effort-intensive and
technically demanding procedure with a long
turnaround time, urging to find alternatives4. In
resource limited countries, semi-automated PCR-
based technologies such as Random amplification
of polymorphic DNA (RAPD) PCR and Repetitive
element palindromic (REP) PCR, remain therefore
the choice of typing. Typing data generated by
these methods are generally available within 12
hours5. There are many studies in which these
typing methods were used to study A.baumannii
isolates exclusively [6]. However, comparison
between these three methods and their cost-
effectiveness in resource limited settings has not
been extensively examined yet.
The aims of this study are to (i) determine
the prevalence of carbapenem resistance genes in
a large series of isolates, (ii) obtain epidemiological
typing data for carbapenem-resistant A.baumannii,
(iii) establish the clonal relationship of Turkish
isolates with the European clones I-III, (iv) compare
different typing methods such as PFGE, RAPD-
PCR and REP-PCR, and their cost-effectiveness
for resource limited countries.
MATERIALS   AND  METHODS
Bacterial isolates
A total of 205 clinical isolates of multidrug
resistant Acinetobacter species isolates were
collected from the Department of Infectious
diseases, Erciyes University Hospital between 2011
and 2012. To establish clonal relatedness we used
European clone I, II, and III (NIPH 527, NIPH 528,
NIPH 1669) provided by Dr. Alexander Nemec,
Laboratory of Bacterial Genetics, National Institute
of Public Health, Prague, Czech Republic. Out of
205 clinical isolates 97 isolates carrying extrinsic
OXA genes were used further for molecular
profiling. Clinical data collected included patients’
age, sex, number of days in hospital prior to
isolation, specimen types, wards, and type of
infection. Isolates were collected by previously
described method7, isolated in pure culture on
Luria-Bertani agar plates, and identified with the
Vitek 2 system (bio-Merieux, Marcy-l’Étoile,
France). Identification at the species level was
reconfirmed with the API 20NE system (bio-
Merieux, Marcy-l’Étoile, France).
Bacterial growth and DNA extraction
All Acinetobacter isolates were grown in
Luria-Bertani broth (BD Laboratories, NJ, USA) at
37°C for 24 h with shaking. Genomic DNA was
extracted using PureLink Spin Column-based kit
(Invitrogen, California, USA).
PCR for resistance gene detection
PCR assays for the presence of
carbapenemase encoding genes (bla
OXA-51-like
,
bla
OXA-23-like
, bla
OXA-24-like
, and bla
OXA-58-like
) were
performed, using AmpliTaq Gold DNA polymerase
(Life Technologies, California, USA) and AmpliTaq
Gold PCR Master mix (Life Technologies, California,
USA) and primers (Table no.1) were designed from
(Invitrogen, California, USA), as previously
described8. The Thermocycler (Sensoquest,
Göttingen, Germany) was programmed as 94°C for
5 min, 30 cycles of 94°C for 25 s, 52°C for 40 s and
72°C for 50 s, and a final elongation at 72°C for 6
min. Amplification products were run on 1.5%
agarose gel in 0.5TAE buffer at, 60 V for 1.5 h, and
bands visualized with GelRed (0.5 mg/L) (Biotium,
California, USA) using a ChemiDoc Imaging
system (Biorad, Califronia, USA).
Random Amplified Polymorphic DNA (RAPD)-
PCR
RAPD-PCR genomic fingerprinting was
performed using AmpliTaq Gold DNA polymerase
(Life Technologies, California, USA) and AmpliTaq
Gold PCR Master mix (Life Technologies, California,
USA) and primers were designed from (Invitrogen,
California, USA). The primer and PCR conditions
were used as previously described9. The Primer 52
14
J PURE APPL MICROBIO, 10(3), SEPTEMBER 2016.
1677AHMED et al.:  STUDY OF CARBAPENEM RESISTANT Acinetobacter baumannii
-GCTTGTGAAC-32  with the following protocol:
initial denaturation at 94°C for 3 min, followed by
34 cycles at 92°C for 30 s, 40°C for 60 s and 72°C
for 3 min, a final single cycle at 92°C for 30 s, 40°C
for 60 s and 72°C for 10 min. Amplification products
were run on 1% agarose gels with 1× TAE buffer at
90 V for 1·5 h, and bands visualized with GelRed
(0.5 mg/L)(Biotium, California, USA) using a
ChemiDoc Imaging system (Biorad, Califronia,
USA).
Repetitive Element Palindromic (REP)-PCR
It was performed using primer pair used
in previously described study [10] REP1 5'-
IIIGCGCCGICATCAGGC-32  and REP2 5'-
ACGTCTTATCAGGCCTAC-32 , the primer REP1
has the nucleotide (I) inosine at ambiguous
positions in the REP consensus sequence. Inosine
contains the purine base hypoxanthine and is able
to base-pair with A, C, G and T. An initial
denaturation at 94 °C for 10 min, followed by 30
cycles at 94 °C for 60 s, 45 °C for 60 s and 72 °C for
2 minutes, with a single final elongation at 72 °C
for 16 minutes u. Amplification products were run
on 1% agarose gels with 1× TAE buffer at 90 V for
1·5 h, stained with GelRed (0.5 mg/L)(Biotium,
California, USA) and bands visualized using a
ChemiDoc Imaging system (Biorad, Califronia,
USA).
Pulsed Field Gel Electrophoresis (PFGE)
Genomic DNA embedded in agarose
blocks was digested with 30U SmaI11 (New England
Biolabs, Ipswich, UK). Agarose gel electrophoresis
was performed in 1% PFGE certified agarose gels
(Biorad, California, USA) in 0.5 X TBE buffer using
a CHEF DR III apparatus (Biorad, California, USA)
for 20 hours at 12ºC. The run conditions were 200
V with a pulse angle of 120° and pulse times of
three phases as follows: 20s for 8h, 10s for 8h and
5s for 4h. A Lambda PFGE ladder (Biorad, California,
USA) was used to provide molecular size markers,
and the gels were stained with GelRed (0.5 mg/L)
(Biotium, California, USA). DNA bands patterns
were visualized using a ChemiDoc Imaging system
(Biorad, Califronia, USA). PFGE, RAPD-PCR and
REP-PCR clusters were interpreted using
Bionumerics software (version 2.5 (Applied Maths,
Kortrijk, Belgium) (Department of Microbiology,
Ospedale San Raffaele Institute, Milan, Italy); using
the Dice correlation coefficient and Unweighted
Pair Group Method with Arithmetic Mean (position
tolerance and optimization of 1.5%).
Cost comparison of molecular typing methods
The costs in Euros of PFGE, RAPD-PCR
and REP-PCR were compared. Material cost (media,
reagents, and commercial kits); instrumentation,
chemicals and lab ware were also calculated.
RESULTS
PCR for Resistance genes
The bla
OXA-51-like
 gene was present in 188
(91.7%) isolates out of 205 isolates collected for 2
years from 2011-2012. Only isolates containing
bla
OXA-51-like
 gene were further processed for PCR
study for other resistance genes such as bla
OXA-
23-like
, bla
OXA-24-like
 and bla
OXA-58-like
. In those isolates,
36(19%) isolates carried bla
OXA-23-like
, 62(33%)
carried bla
OXA-24-like
 and 30(16%) isolates carried
bla
OXA-58-like
 resistant genes.
PFGE, RAPD-PCR and REP-PCR
With 80% similarity cut-off value, a
hundred carbapenem isolates out of 188 isolates
those carrying extrinsic bla
OXA-23-like
, bla
OXA-24-like
,
and bla
OXA-58-like
 genes only, were included for DNA
profiling studies with 3 EU clones as standards.
PFGE typing revealed 13 clusters followed by
RAPD-PCR: 11 clusters and REP-PCR: 8 clusters.
RAPD-PCR showed 23 unique types followed by
PFGE: 15 and REP-PCR showed none unique types.
Consequently, PFGE showed highest
discriminatory index (0.8814) sharply followed by
RAPD-PCR (0.8784) and REP-PCR (0.7261) (Table
no. 2). Discriminatory index was calculated by
using indices of Hunter’s discriminatory formula
(9)  
Analysis of 100 isolates by PFGE showed
11 isolates (Table no.2) within cluster A were similar
to EU I clone. Five isolates belonging to cluster G
and 3 isolates belonging to cluster N were similar
to EU II and EU III clone respectively. European
clones were mainly isolated from Medical ICU
including all 11 EU I clone, (2/5) EU clone 2 isolated
from coronary vascular ICU and Infectious
Diseases Service and (2/3) EU clone 3 from internal
medicine ICU and (1/3) EU clone 3 is isolated from
general surgery ICU.
Clinical Characteristics of the data
Analysis of 100 selected isolates data
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Table 1. Primers Used for Detection of OXA-Like Genes
Resistance gene Primers were taken from previous study (R5) Fragment size
bla
OXA-51-like
52 -TAATGCTTTGATCGGCCTTG-32 353base pairs
52 -TGGATTGCACTTCATCTTGG-32
bla
OXA-23-like
52 -GATCGGATTGGAGAACCAGA-32 501 base pairs
52 -ATTTCTGACCGCATTTCCAT-32
bla
OXA-24-like
52 -GGT TAG TTG GCC CCC TTA AA-32 246 base pairs
52 -AGT TGA GCG AAA AGG GGA TT-32
bla
OXA-58-like
52 -AAG TAT TGG GGC TTG TGC TG-32 599 base pairs
52 -CCC CTC TGC GCT CTA CAT AC-32
Table 2. Typing analysis of A.baumannii using PFGE, RAPD-PCR and REP-PCR methods
Methods Clusters Unique types Discriminatory index
REP-PCR 8 0 0.7261
RAPD-PCR 11 23 0.8784
PFGE 13 15 0.8814
Table 3. Clinical characteristics of the data
Underlying conditions All patients, n (%)
Malignancy 33(16.1)
Liver failure 7(3.4)
COPD 31(15.1)
Diabetes mellitus 42(20.5)
Chronic heart failure 24(11.7)
Kidney failure 41(20)
Hypertension 41(20)
Corticosteroid therapy 51(24.9)
Invasive Procedures in Diagnosis and Treatment
Total parenteral nutrition 62(30.2)
Re-intubation 14(6.8)
Transfusion 118(57.8)
Operation 67(32.7)
Enteral feeding 72(35.1)
Peritoneal dialysis 6(2.9)
Central venous catheter 117(57.6)
Urinary catheter 152(74.1)
Mechanical ventilation 127(62)
Tracheotomy 52(25.4)
Drainage catheter 24(11.7)
Chest tube 25(12.2)
External ventricular drainage 1(0.5)
Bronchoscopy 7(3.4)
Colostomy 8(3.9)
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revealed 28% (28/100) of patients were colonised
and remaining 72% (72/100) were detected with
primary infection. Based on 100 selected isolated,
the Male: Female ratio was 65:35 and the majority
of the patients were aged between 45-75 years old.
Most patients were admitted to hospital for medical
conditions and had one or more predisposing
factors to A.baumannii infections. As noted in
(Table no. 3), the most common underlying
condition was corticosteroid therapy (n=51, 24.9%)
followed by diabetes mellitus (n=42, 20.5%),
malignancy (n=33, 16.1%) and chronic obstructive
pulmonary disease (COPD) (n=31, 15.1%). The
most common invasive diagnosis procedure was
from urinary catheter (n=152, 74.1%) followed by
central venous catheter (n=117, 57.6%). Of all
cases, (n=44, 23.4%) patients admitted to ICU of
which (n=16, 8.5%) patients had most common
reason for admission was respiratory disease.
Cost effectiveness of Typing methods
PFGE apparatus is expensive compared
to any thermocycler (Table no. 4). PCR-based typing
methods are economically thermocyclers can be
used for various PCR based reactions including
typing and technically suitable for resource limited
laboratories in developing countries.   Cost of the
molecular techniques was calculated in which
RAPD-PCR was the most economic method (5
Euros/sample including consumables), however,
PFGE (11 Euros/sample including consumables) is
gold standard but laborious, time consuming (1
week) and expensive REP-PCR (6 Euros/sample
including consumables) was also economic (Table
4).
DISCUSSION
Previous study reported the presence of
European clone II in Turkey2, however, in this study
we have showed the presence of European clone
I, II and III in Turkey. Moreover, EU clone III was
first to be determined in Turkey. Furthermore, the
presence of 11 isolates were similar to EU clone I
lineage isolates, 5 were similar to EU clone II  and 3
were similar to EU clone III speculating wider
multidrug resistance threat within local findings.
Our results support the presence of bla
OXA-23-like
,
bla
OXA-24-like
 and bla
OXA-58-like
. Thirty six isolates
(19%) out of 188 carried bla
OXA-23-likes 
genes, which
is low, compared to other studies reporting 100%12
or high prevalence of bla
OXA-23-like
 some reported
more than 80%13 in Turkey. Presence of bla
OXA-24-
like 
resistance gene was reported in 62 isolates (33%)
which is rarely identified in this geographical region
and this is the first study to report bla
OXA-58-like
genes from Turkey.
Nowadays, there is a growing interest to
analyze A. baumannii infection/colonization
because one of the main problems with A.
baumannii is the difficulty to distinguish true
infection from colonization and to regulate whether
or not the affected patients require therapy against
this pathogen. Furthermore, colonization is main
risk factor for secondary infection and A.baumannii
colonization strains are more resistant to antibiotics
than A.baumannii infection strains14. In the current
study, taking into account all units, the first sources
of A. baumannii isolates were wound/drainage and
skin and soft-tissue samples, representing 26.3%
of all samples. This could be explained by the
ubiquitous dissemination of A. baumannii in all
units from patients with trauma, burns, devices or
invasive medical procedures such as catheters and
drains. Another risk factor for dissemination is the
ability of A baumannii to survive in hospital
environments for an average of 20 days at a relative
humidity of 31%15.
In our setting, 64.8% (122/188) of A.
baumannii isolates were from ICU patients. Thus,
ICU was the main unit with high risk patients of
hospital-acquired A. baumannii infection/
colonization. As described worldwide, A.
baumannii has become a nightmare for many ICUs
with critically ill patients with multiple co-
morbidities, concurrent infections and prolonged
courses of antibiotics16. In ICU patients, A.
baumannii was mostly isolated from the
respiratory tract (20.7%), followed by bloodstream
(19.6%) and urine (10.3%). Thus, the respiratory
tract was the most common site of isolation of A.
baumannii. This is not surprising because A.
baumannii has the propensity to colonize
respiratory or ventilation devices in ICU ventilated
patients. In these patients, it is often difficult to
distinguish upper airway colonization from
ventilator-associated pneumonia.
In addition to this, we also investigated
the use of various molecular typing methods
employed to characterise A.baumannii in resource
18
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limited laboratories. Cost depends of numerous
factors, the amount of initial capital outlay for the
equipment, its depreciation, which will depend on
whether it is out-of-date compared with newer
versions or totally new platforms. The frequency
and care it is used and finally of any modifications
to the working place. In addition, cost of servicing,
the price, and need for the any replacement parts
and consumables should also be considered. In
our study, cost of the molecular techniques was
calculated in which RAPD-PCR was the most
economic method (5 Euros/sample including
consumables), however, PFGE (11 Euros/sample
including consumables) is gold standard but
laborious, time consuming and expensive. PFGE
apparatus is expensive compared to any
thermocycler, which makes it generally
unaffordable in resource limited laboratories (Table
no. 4). Furthermore, thermocyclers can be used for
various PCR based reactions including typing.
Amenability to computerised analysis
and incorporating of the typing results and
electronic database are other important criteria for
typing. Since these factors are important for
longitudinal comparison of large number of
isolates. At local hospital data obtained by robust
typing methods can be analysed electronically or
assessed visually. Visual interpretation of even
small number of isolates requires normalisation of
data prior to inspection17. Nonetheless, since
clones are spreading among hospital and various
geographical areas electronic databases helps
microbiologist and public health institutes to
monitor the spread.  In PFGE, results are analysed
using BioNumerics software and typing results are
incorporated for computer analysis, however,
which costs more than €10,000, which could be a
negative aspect of this technique. With this
software we can analyze RAPD-PCR and REP-PCR
gel bands together with PFGE.
A good typing method should
discriminate between assigned samples to two
different strains sampled randomly from population
of given species. It can be expressed as a probability
using Simpson’s index of diversity. Hunter and
Gatson’s modification of Simpson’s index of
diversity and fixed confidence intervals are
important criteria used to decide strain’s identity
or diversity. In our study PFGE has high
discriminatory power and the results can be
compared by international database called
PusleNet, however, unlike RAPD-PCR and REP-
PCR18.
Stability is another criterion for evaluation
of typing method in which strains markers
assessed by typing method should not change
rapidly or should remain stable during storage and
subculture. Nearly all RAPD markers are dominant,
it is not possible to distinguish whether DNA
segment form heterozygous has amplified or from
homozygous. Furthermore, it is a PCR based
reaction and mismatch between the primer and
template could hinder the product formation.
RAPD-PCR provides a much higher level
of discrimination for less cost of a diverse cohort
to hospital- and community-acquired CD clinical
strains [19]. It should also be recognized that
RAPD-PCR would also be less expensive to perform
if the PCR products were electrophoresed using
an agarose gel instead of specialized agarose gel
for PFGE which is 10 times more expensive.
Considering the overall cost of the technique and
procedure PCR based methods are more
appropriate, however, PFGE has supremacy over
RAPD-PCR and REP-PCR in discriminatory power
and reproducibility. Although further studies
needed to compare these techniques and other
advanced molecular methods.
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Abstract 
Acinetobacter baumannii is clustered with other phenotypically similar species into what has commonly become known as the ACB 
complex: A. calcoaceticus, A. pittii and, A. nosocomialis. The ecology and pathology of most of these species are not well understood, mainly 
because current specific phenotypic techniques have, to date, been insufficient. This has inhibited both the precise identification of, as well as 
the ability to discriminate between, these clinically important and closely related Acinetobacter strains.  However, new genotypic methods 
have greatly enhanced our capacity to identify the ACB complex. This has resulted in the implementation of more rational infection control 
programs. Several genotypic identification methods are explored in this study, including non-polymerase chain reaction (PCR)-based and 
PCR-based methods. These methods include ribotyping, pulsed-field gel electrophoresis, 16S rRNA identification, multilocus sequence 
typing, single locus sequence typing, restriction fragment length polymorphism analysis, restriction analysis of 16S-23S rRNA intergenic 
spacer sequences, rapid amplification of polymorphic DNA, and repetitive extragenic palindromic PCR; however, there is no current single 
ideal genotyping method. Each one has its own advantages and disadvantages. With this in mind we reviewed current and new genotyping 
methods used to characterize the Acinetobacter species.  
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Introduction 
The clinically important and closely related genus 
of the Acinetobacter strain, Acinetobacter baumannii, 
is a most troublesome pathogen, causing hospital-
acquired infections worldwide [1]. It can survive for 
longer periods in hospital settings and is potentially 
capable of causing serious hospital outbreaks. Over the 
last 10 years, the clinical significance of A. baumannii 
has increased through its ability to acquire multi-drug 
resistance and so reduce therapeutic options [2]. In 
most hospital settings, it is increasingly associated 
with nosocomial pneumonia in intensive care units, 
particularly in patients with ventilator-associated 
pneumonia [3,4]. 
Currently, Acinetobacter is split into large groups 
of species. Taxonomy of the genus Acinetobacter has 
revealed 23 valid names and 11 genomic species that 
have been delineated by DNA-DNA hybridization [5]. 
However, identification of Acinetobacter at species 
level is still erratic and for clinical reasons because it 
obscures possible differences in the biology and 
pathology of the individual species. In clinical 
settings, precise identification of species may be 
subject to ramifications in diagnosis, antimicrobial 
therapy, and infection control policies [6]. Associated 
with the A. baumannii strain is a group of 
phenotypically and genetically closely related Gram-
negative bacteria. These are non-motile, aerobic, rod-
shaped bacteria with polar fimbriae, which can have 
oxidase-negative and catalase-positive biochemical 
reactions [7,8]. These particular species have been 
named Acinetobacter calcoaceticus, Acinetobacter 
pittii (formerly referred to as the 
Acinetobacter genomic species 3), and Acinetobacter 
nosocomialis (formerly referred to as 
the Acinetobacter genomic species 13TU). 
Collectively, they are now referred to as the ACB 
complex, having a 16S rRNA sequence identity value 
of between 97% and 99.9% and inter-species values of 
between 65% and 75% [7]. Although the ACB 
complex is considered to be an important nosocomial 
infectious agent, the clustering of A. nosocomialis and 
A. pittii together in an ACB complex is unsatisfactory 
because of the ambiguity in biological and 
pathological differences within the species. An ACB 
complex is often associated with nosocomial 
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infections [9]; however, A. calcoaceticus is 
predominantly an environmental isolate [10]. Thus, 
precise identification of species in an ACB complex is 
essential to determine the pathology, epidemiology, 
and ecology within these species.  
Only few phenotypic techniques have been 
validated to identify clinically important Acinetobacter 
species, with large numbers of strains already having 
been identified by DNA-DNA hybridization [7]. A 
different and largely adopted 19 biochemical test 
pattern developed by Bouvet and Grimont [11] 
identified 12 different Acinetobacter species. Further 
studies revealed its inability to discriminate all 
genomic species identified by DNA-DNA 
hybridization [11,12]. Unfortunately, the 
differentiation of genetically closely related species in 
an ACB complex is not possible using this method. In 
addition, commercially available identification 
platforms were also found to be insufficient and 
inaccurate; they were found to incorrectly identify 
25% of the species belonging to the ACB complex 
[13]. 
 
Genotypic analysis 
Several genotypic methods have been developed 
for identification of Acinetobacter species. 
Nevertheless, despite significant advances in 
genotypic methodology, genotypic identification has 
not, to date, been used very extensively. This is quite 
surprising, as genotypic methods have several 
significant advantages compared to phenotypic 
methods: they have a faster turnaround time and are 
highly sensitive. For example, pulsed-field gel 
electrophoresis (PFGE) is a genome-based non-
polymerase chain reaction (PCR) method and is 
considered to be the gold standard for genotyping [14]. 
Also, the use of phylogenetic analysis using particular 
DNA sequences for identification and genetic 
relatedness has improved over the last ten years. 
Several target DNA sequences are also used for 
species identification studies. In this review, current 
and new genotypic methods used to identify and 
characterize the Acinetobacter species are discussed, 
and a comprehensive assessment of the methods is 
presented. 
 
Ribotyping 
Ribotyping is based on an application of southern 
blotting. Its efficacy in identifying and genotyping 
several bacterial strains has already been proven [15]. 
In this technique, genomic DNA is digested using 
restriction enzymes. The DNA fragments are then 
separated by electrophoresis and transferred to a 
membrane. Next, hybridization using a labelled probe 
specific for ribosomal DNA is done. Non-radioactive 
labels are used, which makes the method easier to 
perform in a well-equipped microbiology laboratory. 
The resulting ribotype profiles could be species or 
strain specific. Gerner-Smidt initiated the 
identification of Acinetobacter species using EcoRI, 
ClaI and SalI as restriction enzymes followed by a 
digoxenin-11-UTP-labeled cDNA probe form the 
ribosomal DNA [16]. Ribotype profiles using HindIII 
were in accordance with amplification and restriction 
fragment length polymorphism analysis (AFLP) 
results for European clones [17]. Furthermore, an 
automated ribotyping system, Riboprinter (Dupont, 
USA), is also marketed, and has been used in several 
studies using EcoRI restriction enzymes [18]. Another 
study, in which 83 isolates were identified using the 
PCR method, showed 100% specificity compared to 
ribotyping, which had 85.5% sensitivity and 93.5% 
specificity. This showed that ribotyping was less 
efficient and less rapid than the PCR method. 
Although ribotyping is laborious, results can be 
compared between laboratories. Species from 
Acinetobacter can be easily differentiated. However, 
this method is less discriminatory than the PFGE 
method [19]. Therefore at present, ribotyping has been 
replaced by the PFGE method. 
 
Pulsed-field gel electrophoresis (PFGE) 
In this method, genomic DNA digested by 
restriction enzymes and large DNA fragments are 
separated by a pulsed electric field. Currently, the 
most commonly used technique is counter-clamp 
homogeneous electric field (CHEF) electrophoresis. In 
this system, the DNA fragments are migrated in a 
zigzag formation through an agarose matrix in a 
pulsed alternating electric field that is kept at a 
consistent temperature of 120°C. Although PCR-based 
methods are currently used because they are 
expeditious, PFGE still remains the preferred method 
of choice and is considered to be the gold standard for 
genotyping. Usually, ApaI and SmaI restriction 
enzymes are used for macrorestriction of the genomic 
DNA for Acinetobacter species typing. When used on 
a set of ACB complexes with the ApaI restriction 
enzyme, PFGE was found to be more discriminatory 
than was the ribotyping method [20]. A comparative 
study, in which a set of ACB complex strains were 
studied and analyzed for inter-laboratory studies, 
showed that PFGE profiles can be compared if 
scrupulously standardized [21]. Thus, this procedure 
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could be a future tool in establishing an international 
database for regional and international monitoring 
strains. However, PFGE equipment and its reagents 
are expensive, and inter-laboratory reproducibility 
possibly still remains a process for implementation at 
some future date. Furthermore, PFGE takes more than 
five days to generate results and needs expensive 
software for such analysis. PFGE is therefore 
laborious and expensive. Other PCR-based genotyping 
methods are usually used, but sometimes both methods 
are used together [20,21]. 
 
16S rRNA sequencing 
16S rRNA gene amplification and sequencing is 
the most commonly used method for bacterial 
identification. The gene is 1,550 base pair (bp) long 
and is composed of both variable and conserved 
regions. It is long enough to provide unique and 
statically compelling measurements. It is a universal 
gene in bacteria, and universal primers are used to 
complement the conserved regions for the 
identification of bacterial species that are difficult to 
identify by ordinary phenotypic methods [22]. The 
efficiency of 16S rRNA gene sequencing depends on 
the application of the correct label to each sequence, 
the deposition of a complete explicit nucleotide 
sequence, and the accurate collation of this 
information into a private or public database. The 
sequencing of 16S rRNA gene method has been used 
for determining a large number of strains. As a result, 
GenBank, the open access databank, has over 90,000 
16S rRNA genes. Due to the successful use of 16S 
rRNA, gene differentiation of many major phyla in 
bacteria at the genus level can now also be done. 
However, there have been some drawbacks with this 
differentiation method, particularly in the case of 
species that have similar sequences. 16S sRNA 
sequencing is not satisfactorily polymorphic to all 
Acinetobacter species because of its extremely slow 
rate of base substitution [12]. On the other hand, the 
RNA polymerase β-subunit (rpoB) gene sequences 
seem to possess better discriminatory powers and 
reliability than does 16S rRNA gene sequencing in 
these specific cases [23]. In another study [24], 99 
well-identified strains of ACB complex were studied 
to assess inter- and intra-species variability using the 
rpoB gene for resultant comparison and 16S rRNA 
differential sequencing. It was found that rpoB 
sequencing identified ACB complex strains more 
accurately than did the 16S rRNA gene sequencing 
methodology. 
 
Multilocus sequence typing (MLST) 
This is a high-resolution genotypic method for 
sequencing microorganisms; it has been applied 
successfully for clinical characterization of many 
important nosocomial pathogens including the 
Acinetobacter species. MLST is a relatively new 
technique that is used as an alternative to PFGE. It was 
designed initially for global epidemiology and 
surveillance. MLST is a process based on multilocus 
enzyme electrophoresis, during which internal 
fragments of housekeeping genes are compared. These 
genes are present within all isolates, and mutations 
within them are considered to be neutral. For every 
gene fragment, different sequences are assigned as 
alleles. Fragments are approximately 500 bp in length, 
and five to eight loci are sequenced. Each isolate is 
characterized by the alleles of each housekeeping loci 
or sequence type [25,26]. The main advantage of 
MLST when compared to other genotyping methods is 
that the data can be shared between laboratories and 
on the internet 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/). 
The internal fragments of the seven loci that can be 
selected for an MLST platform are gltA, gyrB, gdhB, 
recA, cpn60, gpi, and rpoD [26,27]. However, 
according to Hamouda et al. [28], the exclusion of the 
gyrB and gpi genes from the MLST platform could 
improve the accuracy of detection. 
Furthermore, an adeB gene from an efflux pump 
protein could also be used as a marker for MLST. The 
adeB gene makes up a part of the ABC efflux pump 
cluster, which has a built-up resistance to tetracycline 
and aminoglycosides. Huys et al. [29] used adeB gene 
MLST to study 50 pan-European (pE) multidrug-
resistant Acinetobacter baumannii (MDRAB) strains, 
mostly from European hospitals. An internal fragment 
of the adeB gene was investigated to establish whether 
it contained potential polymorphic sites for sequence-
based identification of intraspecific groups in 
MDRAB. Of 50 MDRAB isolates, 11 different adeB 
sequence types were defined, establishing 5 
genotypically unrelated groups and 6 previously 
delineated intraspecific groups. However, little is 
known about the distribution of the adeB gene in 
geographically unrelated isolates. Furthermore, this 
gene is regulated in multidrug-resistant isolates due to 
stringent controls of gene regulation, and it is difficult 
to predict the presence of this gene in an 
aminoglycoside resistance spectrum [30]. MLST is a 
powerful tool to discriminate closely related genomic 
species, and it is comparable to PFGE and 
amplification and restriction fragment length 
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polymorphism analysis (AFLP) [26]. For rapid 
identification (around four hours), multilocus PCR can 
be followed by electrospray ionization mass 
spectrometry (PCR-EIMS). Notwithstanding this, 
PCR-EIMS generates slightly less resolution power 
and less information than does MLST [31]. 
 
Single locus sequence typing (SLST) 
Unlike MLST, which requires amplification and 
sequencing of seven housekeeping genes for 
population structures, SLST requires just one gene. In 
SLST, amplification and sequencing of the blaOXA-51-
like gene is performed; this gene is unique to A. 
baumannii. Although blaOXA-51-like has been 
occasionally identified in A. nosocomialis and A. pittii, 
it is powerful marker for identification of A.baumannii 
if SLST is considered.. Previously, 585 isolates of A. 
baumannii obtained from Greece, Lebanon, Italy, and 
Turkey were studied and evaluated using SLST [32]. 
The performance of SLST was compared with 
Pasteur’s MLST, and PubMLST scheme resulted in 
detection of the same alleles. The reliability of SLST 
was further validated by the analysis of A. baumannii 
whole genome sequence available in GenBank. This 
method can be used in developing countries because it 
is less laborious, faster, and more reliable. 
 
Restriction analysis of PCR-amplified 
sequences 
Restriction of PCR-amplified DNA sequencing is 
an important genotyping marker used for the 
characterization of microorganisms. In this method, 
various conserved sequences are amplified and 
restricted by one or several restriction enzymes. 
Restricted DNA fragments are obtained by 
electrophoresis, and these fragments are used to build 
libraries. Several sequences within the genome are 
targeted, including 16S rDNA, 16S-23S intergenic 
spacer sequences, 16-23S rDNA, and the recA gene 
[17]. 
 
Amplification and restriction fragment length 
polymorphism analysis 
In this method, amplification of internal sequences 
of the recA gene are used for the identification of 
Acinetobacter species, followed by a restriction 
fragment length polymorphism (RFLP) analysis with 
two restriction enzymes. In this method, chromosomal 
DNA is extracted and amplified, DNA sequences are 
restricted with MboI and HinfI restriction enzymes, 
and electrophoresis is performed on 8% agarose gel. 
This technique was documented using 40 clinical 
important Acinetobacter strains [33], where all strains 
were correctly identified to a genospecies level. This 
proved to be a simple tool for the identification of 
Acinetobacter species. However, in another study [34], 
32 strains were typed using recA amplification and 
RFLP analysis, and this method could not identify the 
genospecies of most isolates belonging to the 
Acinetobacter species. Recently, 77 strains, including 
43 Acinetobacter reference strains, were examined. In 
this study, three restriction enzymes were used: MboI, 
HinfI, and Tsp5091. The discriminatory powers of 
Tsp5091 were found to be very satisfactory, generating 
an individual profile for 23 genomic species. 
Furthermore, PFGE is also used as an auxiliary 
method, which adds to the cost of this method [12,35]. 
However, there are unresolved issues in terms of 
reproducibility and inter-laboratory sharing of results. 
In addition, there is no national or international 
database for comparing isolate profiles. 
 
16S-23S rRNA intergenic spacer sequences 
Restriction analysis of 16S-23S rRNA intergenic 
spacer sequences is also a promising approach for the 
identification of Acinetobacter species. The 16S rRNA 
gene sequences of the members of the Acinetobacter 
species have 94% similarity identity. In this technique, 
genomic DNA is extracted and 16S-23S rRNA 
intergenic spacer genes are amplified. Restriction 
analysis of the amplified sequences is done using two 
or more restriction enzymes.  In a previous study [35], 
Acinetobacter strains from ACB complex were 
restricted with AluI and NdeII restriction enzymes, 
which yielded satisfactory restriction patterns. 
Furthermore, southern blotting was performed for five 
to six targets in the DNA of the identified strains, and 
only one fragment per strain was detected. It was 
found that 16S-23S rRNA intergenic spacer sequences 
have a low degree of intra-species variation and high 
degrees of inter-species divergence. In another study 
[7],
 
28 types of strains, including 11 reference strains, 
were used; amplification and restriction of sequences 
was followed by DNA sequencing, revealing low-level 
similarity within the ACB complex. This study also 
demonstrated that internal transcribed spacer (ITS) 
sequences have better discriminatory power than a 16S 
rRNA gene. However, this method takes more than 
two days to complete and it is not suitable for a routine 
diagnostic laboratory [35]. 
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Rapid amplification of polymorphic DNA 
(RAPD) 
This is one of the easiest genotyping methods to 
evaluate strain-level fingerprinting, using PCR and 
consequently performing gel electrophoresis. No 
knowledge of the DNA target sequence is required, as 
a primer anchors to a non-specific site in the DNA 
sequence. The primer target sites may vary in number 
and location over the genome; accordingly, the size 
and number of the amplified fragments differ. Usually, 
decamer (10 nucleotides) lengths of non-specific short 
sequence primers are used under low annealing 
temperature, and electrophoresis RAPD profiles can 
be used for strain genotyping. Various primers and 
protocols have been used to type the Acinetobacter 
species [27,36]. Recently, a melting curve analysis 
was performed for the amplified DNA fragments that 
were generated during RAPD. This approach does not 
require electrophoresis and ethidium bromide by real-
time PCR, thus greatly reducing workload and overall 
time [37]. RAPD has many advantages: it requires 
low-cost primers, only a small quantity of DNA for 
analysis, and it requires no blotting or hybridization. 
However, the introduction of commercial and 
standardized reagents made RAPD fingerprinting 
more time consuming to standardize. Thus, exchange 
and comparison of RAPD profiles between 
laboratories has become more difficult, and it has 
become impossible to produce accurate results. A 
multicenter study was conducted by Grundmann et al. 
[38] in seven laboratories across six European 
countries to evaluate the reproducibility of RAPD 
profiles of 40 isolates within the ACB complex using 
standardized protocols and reagents. The outcome of 
these efforts by three of the centers to improve inter-
laboratory reproducibility was unsatisfactory. 
Nonetheless, PCR with standardized protocol, 
reagents, and primers (DAF4 and M13) produced 
unhindered banding patterns [39]. These patterns are 
strain specific; RAPD could therefore be a useful 
approach for epidemiological genotyping. However, 
inter-laboratory data exchange remains an unresolved 
issue. 
 
Repetitive extragenic palindromic (REP)-PCR 
There are many repetitive (strain coding and non-
repetitive) DNA sequences spread throughout the 
genome that can be used as markers for identification. 
PCR primers can be constructed for REP sequences to 
amplify the DNA between these sequences when two 
REP sequences are in close proximity [40]. The 
regions occupied between the REP sequences vary in 
size due to heterogeneity among the separate strains; 
thus, different sizes of the fragments are amplified. 
Fragment amplification generates unique profiles 
following gel electrophoresis. These profiles (band 
patterns) can be compared to other genotypes. The 
REP-PCR results are comparable to other genotypic 
characterization techniques, including PFGE [41,42]. 
Intra-laboratory reproducibility in commercially 
available REP-PCR-based methods occurred more 
than 98% of the time when the process was tested in 
triplicate. However, it was not made clear how the 
triplicates performed [42]. One of the main drawbacks 
of REP-PCR is the use of traditional agarose gel 
electrophoresis, which lacks reproducibility; this may 
result in the variation and use of different 
electrophoresis systems.  
The DiversiLab (Biomerieux, Marcy L’Etoile, 
France) system using the REP-PCR approach is a 
semi-automated technique used in many hospitals 
worldwide. A number of commercially available 
detection kits have been developed for various 
bacterial species including Acinetobacter. In this 
method, PCR is followed by a separation of the 
amplified genomic DNA regions between the 
repetitive elements using chip-based micro-fluidic 
capillary electrophoresis. This process increases 
reproducibility and the resolution of the REP-PCR 
approach in comparison with the traditional gel 
electrophoresis method. The resulting data is 
automatically collected and analyzed by DiversiLab 
software. Various studies have shown many 
advantages of using DiversiLab: it is easy, simple, 
rapid, and yields reproducible results. In addition, 
when DiversiLab was compared with PFGE and 
arbitrary PCR methods for the characterization of an 
outbreak (caused by resistant and susceptible A. 
baumannii) involving 29 patients, isolates showed 
similar antibiotic resistance patterns. In another study 
[43], in which 21 isolates of A. baumannii were 
studied and results were compared with ribotyping, 
DiversiLab appeared to be more discriminatory than 
ribotyping was, distinguishing eight different clusters 
compared to only six different clusters distinguished 
by ribotyping. However, the installation of the 
DiversiLab system is expensive, especially in 
resource-limited laboratories. The overall cost of 
reagents and consumables for this system is also much 
higher than for PFGE. Since inter-laboratory 
reproducibility of REP-PCR approaches are limited, 
large-scale inter- and intra-laboratory studies are 
required to assess the efficiency of the DiversiLab 
system. 
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Conclusions 
In recent years, substantial improvements in 
genotyping methods have changed the current 
approaches to identifying Acinetobacter species. This 
has involved major improvements in bioinformatics, 
automation, and technical advances in genotyping 
methods. The steadily increasing genotypic databases 
allow for rapid and easy assessments between 
laboratories to enable comparisons and 
epidemiological surveillances of Acinetobacter species 
to be made. However, it remains regrettable that there 
is no absolute genotypic method. Every genotypic 
approach has its own benefits and drawbacks. 
Accordingly, one or more genotypic approaches can 
be used, but this is dependent upon the laboratory 
setting and the available financial support. Ribotyping 
also has good discriminatory powers in assessing the 
ACB complex; however, a banding patterns complex 
and libraries of profiles of well-defined strains are 
required for species identification. If a quick analysis 
is important (e.g., in the event of an all-encompassing 
local outbreak), then PCR-based methods such as 
DiversiLab can be used. However, if the outbreak is 
disseminating to various geographical regions, more 
robust techniques such as PFGE should be used, 
because this method makes it easier to compare results 
obtained in different laboratories. New methods such 
as MLST are as effective as PFGE because immediate 
results can be obtained. Although MLST is quick and 
reliable, it still requires an expensive system to be 
implemented, well-trained staff, quality controlled 
laboratories, and a large budget for consumables. It is 
easier to implement the MLST and PFGE methods 
locally, but national or international surveillance needs 
to standardize its techniques. In addition, availability 
of resources is a question in developing countries; 
SLST could be another option for provisional 
genotyping, since it is cheaper and faster. Currently, 
PFGE and MLST remain the most widely used 
genotyping methods for the Acinetobacter species.  
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INTRODUCTION
In recent years, nosocomial infections caused 
by Gram-negative pathogens with multiple 
antibiotic resistance have become an import-
ant problem worldwide (Cisneros et al., 1995). 
Acinetobacter baumannii is an oppurtunistic 
pathogen that can lead to serious nosocomial 
infections in patients on long-term treatment 
with broad-spectrum antibiotics and immu-
SUmmaRy
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Acinetobacter baumannii is the most common species to have developed resistance to antibiotics. Due to increasing levels 
of drug resistance, the available therapeutic options are insufficient in A. baumannii infections. This study investigated 
the efficacy of doripenem monotherapy versus doripenem combination therapy with sulbactam, amikacin, colistin and 
tigecycline in experimental sepsis. A carbapenem-resistant A. baumannii was used to develop a sepsis model in 8-10-week-
old Balb/c mice by intraperitoneal injection. Antibiotic therapies were initiated two hours after injection of bacterial 
suspension. Necropsy was performed at 24, 48 and 72 hours and cultures were made from heart, lung, liver and spleen 
samples. Bacterial loads of lung and liver were calculated as CFU/g. Combination therapies with doripenem were more 
effective than monotherapy at 24 and 48 hours of infection but no differences between groups were detected at 72 hours. 
The combination of doripenem with tigecycline and amikacin began to eradicate the bacterial load of lung and liver after 
48 hours of infection, whereas doripenem+sulbactam and doripenem+colistin were started to eradication at 72 hours. The 
results of the study showed that combination therapies with doripenem are more effective than monotherapy and the com-
bination of doripenem with tigeycline or amikacin has more rapid bactericidal effect than that with sulbactam or colistin.
KEY WORDS: Acinetobacter baumannii, Experimental sepsis, Antibiotic therapy.
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nosupressed patients (Poirel and Nordmann, 
2006; Perez et al., 2007; Novak et al., 2012). 
Infections caused by multi-drug resistant 
Acinetobacter spp. are generally more com-
plicated to treat than the infection caused by 
susceptible strains (Sheng et al., 2011; Deve-
ci et al., 2012). Although carbapenems are the 
most popular antibiotics for these infections, 
carbapenem-resistant A. baumannii is a seri-
ous problem in many centers (Oliveira et al., 
2008; Marti et al., 2009; Lambiase et al., 2012; 
Llaca-Diaz et al., 2012). The deficiency of new 
antimicrobial agents with activity against 
multidrug-resistant Gram-negative microor-
ganisms has led to the combination of alterna-
tives to offer better therapeutic results (Kempf 
et al., 2012). Therefore, in recent years many 
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in vitro and in vivo studies have investigated 
combination therapies for carbapenem-resis-
tant A. baumannii infections (Pachon-Ibanez 
et al., 2010; Lee et al., 2008; Housman et al., 
2013; Principe et al., 2013; Dinc et al., 2013). 
For instance, our recent experimental study 
evaluated the therapeutic efficacy of sulbac-
tam in monotherapy and combination with 
colistin, tigecycline and imipenem against a 
sepsis model with carbapenem-resistant A. 
baumannii. We found that the addition of sul-
bactam to imipenem showed better bactericid-
al activity than imipenem monotherapy (Dinc 
et al., 2013). 
Doripenem is a newly marketed carbapenem 
with an in vitro activity against Gram-positive, 
Gram-negative, and anaerobic microorganisms 
and is also more stable against carbapenamas-
es than other carbapenems. Thus, doripenem 
has been considered a valuable addition to the 
options available for the treatment of serious 
bacterial infections caused by multidrug-resis-
tant Gram-negative infections in hospitalized 
patients (Keam, 2008; Dedhia and McKnight, 
2009; Queenan et al., 2013). This study aimed 
to investigate the in vivo efficacy of doripenem 
monotherapy versus doripenem combination 
therapy with sulbactam, amikacin, colistin 
and tigecycline in an experimental sepsis mod-
el with a carbapenem-resistant A. baumannii 
strain. 
maTERIaLS aND mETHODS
Challenge microorganism: This study used a 
carbapenem-resistant A. baumannii strain car-
rying OXA-51, OXA-58 and PER-1 genes isolat-
ed from a patient with nosocomial sepsis. The 
strain was provided by the Department of Mi-
crobiology, Faculty of Medicine, Istanbul Uni-
versity. 
Antibiotics: The antimicrobial agents used in 
this study were the following: doripenem (John-
son & Johnson Industry, Turkey), amikacin 
(Zentiva, Turkey) sulbactam (Mustafa Nevzat 
Pharmaceutical, Turkey), colistimethate sodi-
um (Koçak Farma, Turkey), tigecycline (Wyeth, 
UK). 
In vitro study: MIC determinations for doripe-
nem, amikacin, sulbactam, colistin and tigecy-
cline were performed by Etest (Diagnostic Lio-
filchem, Italy) according to the manufacturer’s 
guidelines. A. baumannii suspension prepared 
to 0.5 MacFarland was cultured in Mueller Hin-
ton Agar (Lab M Ltd, UK) and Etest strips were 
put in agar for 24 hours of incubation. Esche-
richia coli ATCC 25922 was used as the internal 
control. The MIC breakpoints for A. bauman-
nii against to doripenem, amikacin, sulbactam, 
colistin and tigecycline were established ac-
cording to CLSI M07-A9 guidelines (2012) and 
EUCAST Version 3.1 (2013).
In vivo experiments
Mice sepsis model and antibiotic therapies: Bal-
b/c male mice, aged 8-10 weeks weighing 20-25 
g were supplied by Hakan Cetinsaya Experi-
mental and Clinical Research Center / Erciyes 
University, Kayseri, Turkey. The mice were shel-
tered in distinct cages and fed ad libitum food 
and water. Mice were housed in a room with 
light controlled in 12 h day-night periods. This 
study was approved by the Local Ethical Com-
mittee for Animal Studies of Erciyes University 
(No: 11/63).
Animals were randomised into control (pos-
itive and negative) and treatment groups 
(doripenem, doripenem+colistin, doripene-
m+tygecycline, doripenem+sulbactam and 
doripenem+amikacin). One hundred and five 
mice were included in this study and each 
group had 15 mice comprising 5 mice in sub-
groups for each time point of 24, 48 and 72 h. 
To create sepsis, except for the negative con-
trol group, mice were injected intraperitone-
ally (ip) with 0.5 ml 108 cfu/ml A. baumannii 
suspension which was determined in a pre-
study. Antimicrobial therapies were started 2 
hours after injection of bacterial suspension. 
Tigecycline 20 mg/kg, sulbactam 240 mg/kg, 
colistimethate sodium 5 mg/kg, amikacin 15 
mg/kg and doripenem 150 mg/kg were divided 
into two doses and administered every 12 h by 
ip. Drug dosages were determined according 
to pharmacokinetic and pharmacodynamic 
information from previous experimental stud-
ies (Song et al., 2009; Bretonnière et al., 2010). 
Mice were killed at 24, 48 and 72 h post-in-
fection with ip injection of overdose anesthet-
ic (150 mg/kg ketamine hydrochloride, Pfiz-
er, Turkey). The lung, liver, heart and spleen 
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samples were cultured on Tripticase Soy Agar 
(Merck, Germany) to verify whether sepsis de-
veloped or not. In addition, 10-fold dilutions 
of lung and liver homogenates were processed 
to obtain quantitative counts as CFU/g at each 
time point. The bacterial counts at 24, 48 and 
72 h in lung and liver were compared between 
the control and study groups.
Statistical analysis: Results were analyzed using 
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Log-
arithmic transformations were used for statisti-
cal analysis. All bacterial counts were present-
ed as mean ± standard error of mean. One-way 
analysis of variance (ANOVA) and T test were 
used when appropriate to compare differences 
between groups. Student-Newman-Keuls meth-
od was used to analyse intergroup differences. 
When the P-value was <0.05, differences were 
considered statistically significant.
RESULTS
In vitro study: The MIC values for OXA-51, 
0XA-58, PER-1 positive A. baumannii were 6 
μg/ml for doripenem, 48 μg/ml for amikacin, 1 
µg/ml for colistin, 1 µg/ml for tigecycline, 16 µg/
ml for sulbactam.
In vivo experiments
Efficacy of antibiotics: The bacterial counts in 
lung and liver tissues for all groups are shown 
in Table 1 and Figure 1. The lung and liver bac-
terial counts were statistically different between 
the control and treatment groups for all time 
points (P<0.05). At 24 h, combination therapies 
were more effective than doripenem monother-
apy. While there were no significant differences 
between doripenem+sulbactam and doripen-
em+colistin efficacies, doripenem+amikacin 
TABLE 1 - Therapeutic effects of antibiotics on lung and liver bacterial counts.
Groups
Bacterial counts (Mean±SEM)
Lung (Log10 CFU/g) Liver (Log10 CFU/g)
24 h 48 h 72 h 24 h 48 h 72 h
Control (n=15) 7.76±0.10a 7.78±0.06a 5.12±0.28a 8.14±0.19a 7.43±0.32a 5.54±0.44a
Doripenem (n=15) 6.64±0.42a,b 4.09±0.19b 2.10±0.55b 6.89±0.29a,b 4.05±0.24b 1.99±0.52b
Doripenem+sulbactam (n=15) 4.84±1.19b,c 1.69±0.54c 0.84±0.52b 4.79±1.23b,c 1.88±0.33c 0.98±0.60b
Doripenem+colistin (n=15) 4.76±0.84b,c 2.36±0.62c 0.96±0.65b 4.80±0.88b,c 2.25±0.62c 0.90±0.63b
Doripenem+amikacin (n=15) 3.47±0.45c 0.96±0.62c 0.38±0.38b 3.44±0.47c 0.96±0.62c 0.43±0.43b
Doripenem+tigecycline (n=15) 2.47±0.51c 1.11±0.69c 0.97±0.6b 2.21±0.66c 1.05±0.67c 0.94±0.62b
SEM: Standard error of mean. a,b,cStatistically significant differences between groups indicated by different letters in same column (P<0.05). 
FIGURE 1 - Results of colony counts in lung (A) and liver (B) at 24, 48 and 72 h of therapy. DOR, doripenem; 
SUL, sulbactam; COL, colistin; AMK, amikacin; TIG, tigecycline. 
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showed better bactericidal activity than these 
treatments but the tigecycline combination did 
not. There were no statistical differences in the 
bacterial loads of lung and liver among com-
bination therapies (P>0.05). However, all com-
bination groups showed a better efficacy than 
the monotherapy group at 48 h. At 72 h, mono-
therapy and combination therapies showed the 
same results on the bacterial counts of lung and 
liver. Doripenem combinations with tigecycline 
and with amikacin showed faster bactericidal 
activity than with colistin and with sulbactam. 
The doripenem+tigecycline combination was 
the most effective therapy decreasing bacterial 
counts in all groups.
DISCUSSION 
Multidrug resistant (MDR) Acinetobacter spp. 
strains threaten successful treatment of in-
fections, especially in critical care patients 
worldwide. Carbapenems are the most active 
agents against MDR Acinetobacter spp. strains. 
However, due to the overuse of carbapenems, 
many centers have faced the emergence of 
carbapenem-resistant Acinetobacter spp. and 
the incidence is reported to be over 50% (Gar-
za-Gonzáles et al., 2010; Alp et al., 2012; Hou 
et al., 2012; Lemos et al., 2013). In our recent 
study, this rate was detected to be 92% in inten-
sive care units with a high crude mortality (Alp 
et al., 2012). Due to the emergence of resistance 
against different classes of commercially avail-
able antimicrobials, colistin has been recon-
sidered as a therapeutic option. However, the 
clinical effectiveness of colistin is still doubtful 
and very low rates have been reported by differ-
ent researchers (Montero et al., 2004; Falagas 
and Kasiakou, 2005; Motaouakkil et al., 2006; 
Kalin et al., 2013). Although combination ther-
apies may be alternative therapeutic options 
for better clinical efficacy, there are limited 
data on these therapies. (Roberts et al., 2001; 
Pachón-Ibánez et al., 2010; Lemos et al., 2013). 
In our very recent study, sulbactam efficacy in 
mono and combined therapies was evaluated 
in a carbapenem-resistant A. baumannii sepsis 
model (Dinc et al., 2013). In that study, colis-
tin monotherapy was found to be the most ef-
fective therapy and only sulbactam+imipenem 
had better efficacy than imipenem monothera-
py. However, Pantopoulou et al. (2007) reported 
that the combination of colistin and rifampicin 
was more effective than colistin monotherapy 
in experimental infection with multiresistant A. 
baumannii. Another experimental study found 
that colistin monotherapy was not the best 
choise for carbapenem-resistant strains (Mon-
tero et al., 2002). In the studies of Montero et al. 
(2004) and Pachón-Ibánez et al. (2010), imipe-
nem, sulbactam or colistin combinations with 
rifampin or rifampicin were found to be more 
efficient than colistin monotherapy. In addi-
tion, our very recent clinical study investigating 
the efficacy of colistin and colistin+sulbactam 
therapies for patients with ventilator-associated 
pneumoniae due to MDR A. baumannii found 
that bacterial clearance was better in the com-
bination group (Kalin et al., 2013). 
Due to increased resistance among A. bauman-
nii strains against commonly used carbapen-
ems, doripenem being the newest carbapenem 
has become the drug of choice for clinicians. 
However, there few studies have reported on 
the activity of doripenem mono and/or combi-
nation therapies on MDR-resistant bacterial in-
fection around the world. Housman et al. (2013) 
compared mono and combination therapies 
with ampicillin+sulbactam, doripenem and 
tigecycline against MDR A. baumannii in an in 
vitro pharmacodynamic model, demonstrating 
that aggressive doses of ampicilin+sulbactam 
combined with tigecycline or doripenem may 
be good option for these infections. Principe 
et al. (2013) investigated the in vitro activity of 
doripenem and its combinations with colistin, 
tigecycline and amikacin. Doripenem showed 
in vitro synergistic activity in combined forms 
against doripenem-resistant A. baumannii 
strains, suggesting that these results may offer 
in vivo novel combination therapies. Queenan 
et al. (2013) evaluated the in vitro and in vivo 
synergy of doripenem+levofloxacin or cipro-
floxacin and reported that doripenem+levo-
floxacin combination may provide a clinical 
advantage for treatment of non-susceptible A. 
baumannii infections. The present study in-
vestigated the efficacy of doripenem, which is 
more stable against beta-lactamases and shows 
broad-spectrum activity than imipenem, in 
monotherapy and in combination with current 
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therapeutic options (sulbactam, colistin, tige-
cycline, amikacin). As a result, the combina-
tion therapy had a better efficacy on bacterial 
clearance than doripenem monotherapy at 48 
h. Among the combination groups, the com-
bination of doripenem with tigeycline or ami-
kacin had more rapid bactericidal effect than 
sulbactam or colistin.
Several studies reported that tigecycline and 
sulbactam show in vitro activity to carbapen-
em-resistant A. baumannii, but there are still 
doubts about combination therapy in clini-
cal studies (Rodríguez-Hernández et al., 2001; 
Song et al., 2007; Sheng et al., 2011; Deveci et 
al., 2012; Kalin et al., 2013). Sulbactam has 
been reported to show synergistic activity with 
tigecycline, colistin and carbapenems (Monte-
ro et al., 2002; Song et al., 2009; Pongpech et 
al., 2010; Sheng et al., 2011; Deveci et al., 2012; 
Kempf et al., 2012). In addition, some experi-
mental infection models have shown that imi-
penem, meropenem or rifampicin combina-
tions with sulbactam are more effective than 
monotherapy (Ko et al., 2004; Pachón-Ibánez et 
al., 2006). Regarding tigecycline, in previous ex-
perimental studies combination therapies with 
tigecycline have been reported to decrease the 
bacterial load of tissues (Entenza et al., 2009; 
Yilmaz et al., 2012). The present study showed 
similarities with these previous studies. In the 
case of amikacin, Bernabeu-Wittel et al. (2005) 
reported that although amikacin and imipenem 
had synergistic effects on experimental multi-
resistant A. baumannii pneumonia, the in vivo 
effects of combination therapy were not superi-
or to imipenem monotherapy. However in this 
study, the combination with amikacin had a 
rapid bactericidal effect at 48 h.
In conclusion, although doripenem is the 
newest addition to the carbapenems and it 
shows activity against Gram-positive bacte-
ria, Gram-negative bacteria, including extend-
ed-spectrum β-lactamase-producing strains, 
and anaerobic pathogens (Keam, 2008; Dedhia 
and McKnight, 2009), the present study indi-
cated that combination therapies with doripe-
nem were better than doripenem monotherapy 
in terms of bacterial clearance of lung and liver 
at 48 h. Amikacin and tigecycline appear to be 
the most effective agents in combination with 
doripenem. However, these data have to be 
supported by advanced clinical research to de-
termine the best therapeutic choice in serious 
carbapenem-resistant A. baumannii infections.
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Abstract
While colistin remains a last resort agent to treat multi-drug resistant Acinetobacter baumannii, resistance to
colistin has been reported throughout the world. The resistance has been attributed to mutations in lipid A
biosynthesis genes and point mutation in PmrAB-two component response regulator and sensor kinase system. The
emergence of plasmid mediated colistin resistance (mcr-1), in multidrug-resistant enterobacteriaceae raised
concerns, though mcr-1 has not yet been reported in A. baumannii. Lately, colistin resistance has been attributed to
efflux pumps belonging to RND family. While various reports of emergence of colistin resistance are associated with
previous treatment with colistin, other reports concern patients without any prior therapy.
Keywords: Colistin resistance; A. baumannii; Global reports;
Nosocomial pathogen
Introduction
Acinetobacter baumannii is a Gram negative, non-fermenting,
opportunistic isolate, that is recognized as a major nosocomial
pathogen. It can cause infections at various anatomical sites;
bacteremia, pneumonia, meningitis and urinary tract infection, most
commonly in immunocompromised and critical care patients. The
capacity to endure on dry surfaces and its relative resistance to
disinfectants allows this non-fermenter to survive well in the hospital
environment [1]. A. baumannii isolates are resistant to almost all
available antibiotics including β-lactams, fluoroquinolones,
tetracyclines, aminoglycosides and carbapenems [2]. More
importantly, pandrug-resistant and extremely drug-resistant isolates
have emerged [3] and are on the rise worldwide. Colistin (polymyxin
E) and tigecycline are frequently the only antibiotics remaining to treat
multidrug resistant (MDR) A. baumannii infections [4]. However,
hetero-resistance and resistance against colistin have been reported in
clinical settings throughout the world [5]. Here we review the reports
all over the world and epidemiology of colistin resistance in A.
baumannii.
Resistance against Colistin
Colistin, a natural substance produced by Bacillus polymyxa and a
cationic lipopeptide (cyclic decapeptide) discovered in 1949. It has not
typically been included in regimens to treat Acinetobacter infections
because (Albeit debatable) of its neurotoxicity and nephrotoxicity.
However, it has been as a therapeutic option for the treatment of
ventilator associated pneumonia caused by drug resistant gram-
negative organism [6]. Colistimethate sodium and Colistin sulfate are
two commercially available forms and recently colistin has
progressively been used as rescue therapy for severe infections in
critically ill patients [7]. It is bactericidal against Gram negative
bacteria; its amphiphilic nature allows it to interact with lipid A moiety
of lipopolysaccharide (LPS) causing disarray in the bacterial
outermembrane. Colistin is consists of cyclic heptapeptide covalently
attached to a fatty acyl chain [8]. Typically colistin resistance is by
chromosomally mediated modulations. There is relatively little
research has been done on colistin resistance in A. baumannii and
there are two main hypotheses of colistin resistance.
The first hypothesis of colistin resistance is mediated by loss of LPS
production, caused by mutations in any of lipid A biosynthesis genes
(lpxA, lpxC and lpxD) terminating complete production of LPS.
Furthermore, presence of insertion sequence ISAba11 in either lpxC or
lpxA not only causes loss of LPS production but also causes high level
colistin resistance [9]. In countering to total LPS loss, A.
baumannii modify the expression of critical transport and biosynthesis
systems associated with modulating the composition and structure of
the bacterial surface. Eventually, LPS deficiency causes less negative
charge and thus might be the reason for the loss of affinity towards
colistin [10].
Secondly, colistin resistance has been hypothesized to PmrAB-two
component response regulator and sensor kinase system. This system
allows bacteria to sense and respond to various environmental
conditions such as pH or Fe3+ and Mg2+ levels, also affecting
expression of genes implicated in lipid A modification and thus
causing colistin resistance [11]. Point mutations in pmrA and pmrB
genes of PmrAB two-component regulatory system showed
upregulated expression of pmrAB. The increase expression results in
remodeling of bacterial membrane causing decreased membrane
permeability [12].
Recently, colistin resistance has shown to be singularly due to
plasmid mediated mcr-1 gene. Although there is no report of mcr-1
being detected in A. baumannii, the prevalence has been investigated
in E. coli and K. pneumoniae [13,14]. If mcr-1 gene is similar to
NDM-1 colistin resistance could become endemic in the world. The
rapid dissemination of previous antibiotic resistance indicates that,
with the advent of transmissible colistin resistance, progression of A.
baumannii from multidrug to pandrug resistance is unavoidable.
Although the levels of maximum inhibitory concentration of colistin
are not high (4–8 mg/L), acquaintance of mcr-1 by carbapenem
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resistance A. baumannii isolates will make them resistance to all
antibiotics [14]. The potential of mcr-1 to become global depend upon
several factors: use of irrational doses of colistin, the stability of mcr-1
mediated plasmid and their ability to transfer in humans. Effective
strategies that limit selection and further dissemination of plasmid-
associated mcr-1 are clearly needed. It is important to prevent the
dissemination of colistin by developing agents which provide effective
reverse resistance strategies.
Lately, colistin resistance has been found due to efflux pumps [15] in
which efflux pump inhibitors (EPIs) were used to suppressed colistin
resistance. Colistin resistance has been attributed to efflux pumps
belonging to RND (resistance-nodulation-cell division) family [16].
The efflux pump consists of two component regulatory system
mediating adaptive response of bacterial cells to a range of
environmental stimuli. Genes are organized as operon adeA, adeB, and
adeC and regulated by adeR gene. adeA is a membrane fusion protein
and adeC is an outer membrane protein channel, in which adeB
acquire its substrate and transports from cytoplasm or within
phospholipid bilayer to extracellular medium [17].
Global Epidemiology of Colistin Resistance
Colistin resistance has been reported all over the world. The highest
resistance was reported from Asia followed by Europe and others parts
of the globe. Colistin resistance have been uncommon during 90s,
however, the first case was reported from Czech Republic in 1999 [18].
The Clinical and Laboratory Standards Institute (CLSI) has selected an
MIC of ≤ 2 μg/ml as susceptible and an MIC of ≥ 4 μg/ml as resistant
for colistin [19]. Furthermore, SENTRY antimicrobial surveillance
reported from 2006 to 2009 showed Acinetobacter isolates with
polymyxin B MIC ≥ 4 μg/ml were detected in all regions with highest
occurrence in the USA (1.1%), followed by Latin America (0.9%), the
APAC region (0.7%) and Europe (0.4%) [18]. Indeed, a surveillance
study of USA hospitals revealed that all 5.3% of all Acinetobacter
isolates are resistant to colistin [20]. Since then, there are numerous
reports across the world increasing every year. Emergence of colistin
resistant A. baumannii has been observed in several countries;
moreover, since 2011 many reports were recorded. In most of the cases,
colistin resistance was attributed to mutations in lipid A biosynthesis
genes and PmrAB two-component regulatory system. The bacteria
were isolates from sputum, nasal aspirate, wound, urine; however,
blood remained predominant source of isolation.
Most of the reports observed colistin resistance at ≥ 4 μg/ml;
however, some reported higher folds of resistance. A study from
Australia [19] reporting colistin heteroresistant isolates 15 A.
baumannii by population analysis profiling (PAP). The  clinical isolate
contained resistant subpopulations that grew in the presence of up to
10 μg of colistin (sulfate)/ml, even though both had an MIC of 1.0
μg/ml and one isolate was able to grow in MIC >128 and 32 μg/ml,
respectively. Case histories of the patients showed from whom the
isolates in the study were obtained had not been exposed previously to
colistin, since it was only recently introduced in this hospital due to
infections caused by multidrug-resistant A. baumannii; it is never used
by inhalation or for prophylaxis. Thus, the heteroresistance observed in
the present study is unlikely to be related to previous exposure to
colistin. As a result of the substantially decreased proportion of the
colistin-resistant subpopulations after passage in drug-free broth it is
very likely that they were not stable mutators. Heteroresistance has
been noticed in many countries including Italy [21], in which no
colistin resistant isolate was found in ICU survey took place in October
2008-march 2009; however, restricted outbreak of colistin resistance
were recorded in different time periods. In the first case colistin
resistant isolate was recovered on the day 20th of hospitalization in
January 2010. Approximately a year later 3 cases of colistin resistance
were identified from two patients hospitalized three months apart.
Another study from USA [20] reported high mortality rates among
almost all patients suffering from ventilator-associated pneumoniae
treated with colistin combination therapy in the presence of colistin
resistance. The clinical importance of colistin-resistant strains may be
seen in the context of heteroresistance in A. baumannii strains and the
emergence of colistin-resistant pathogens following treatment of MDR
isolates with colistin [21,22]. In Argentina [23] heteroresistance was
determined by plaque efficiency in 14 isolates of them with a greater
than 8 fold increase in MIC in some cases summarized in Table 1.
Country Colistin MIC (μg/mL) and
resistance
Number of
isolates
Source Year Antibiotic therapy Mortality Ref.
Australia 3-10 (heteroresistance) 15(93.7%) sputum, nasal
aspirate, wound,
blood, urine,
bronchoalveolar
lavage samples 
2006 no data no data [19]
Taiwan 4 14(10.4%) blood 2012 no data no data [31]
South Korea 4 11(100%) blood 2014 no data no [32]
Japan 4 (colistin resistance noticed
after therapy)
1(100%) sputum 2015 yes ( piperacillin,
tazobactam,
colistin,
minocycline)
no [30]
USA 4-256 (colistin resistance noticed
before therapy)
20(100%) sputum, nasal
aspirate, wound,
blood, urine,
bronchoalveolar
lavage samples 
2015 yes (colistin,
doripenem,
ampicillin-
sulbactam)
30 day mortality
6 out of 20
patients
[20]
Argentina 2-16 (colistin heteroresistance) 14(18.7%) blood 2011 no data no [23]
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Iran 4 8(13%) blood, bronchial
secretions
2015 yes (colistin,
rifampicin,
tigecycline)
no [16]
Jordon 4 2 (1.7%) blood, sputum, urine,
pus swab
2015 no data no [33]
India 0.016-256 (colistin resistance
noticed after therapy)
8(16%) urine 2011 yes (colistin,
tigecycline,
carbapenems)
no [34]
Saudi Arabia 4 61(4.7%) blood 2013 no data no data [28]
Kuwait 0.016-256 30 (12%) respiratory tract,
postoperative wound,
urine, blood,
cerebrospinal fluid
(CSF)
2011 no data no [29]
Tunisia 2 (colistin resistance noticed
after therapy)
1 (Case report) blood 2015 yes (rifampicin,
amikacin and
colistin)
no [35]
Algeria 16 1 (Case report) blood 2015 no data no data [36]
Egypt 4-8 2(5%) drain, urine 2014 no data no data [37]
Romania 4 2(1%) blood, urine 2014 no data no data [38]
Greece 16-64 86(7.7%) blood, bronchial
secretions
2015 no data no data [5]
Portugal 4 9(4%) blood, bronchial
secretions
2007 no data no data [39]
Turkey 4 1(2.5%) bronchial secretions 2015 no data no data [40]
Italy 32-256 (colistin resistance
noticed before therapy)
9(34.6%) blood, sputum, urine,
pus swab, bronchial
secretions
2014 yes (colistin,
meropenem,
tigecycline,
teicoplanin,
rifampicin)
no data [21]
Spain 4 (colistin resistance noticed
after therapy)
1 (Case report) blood 2011 yes (vancomycin,
meropenem,
sulbactam,
cefepime)
no [26]
France 4 (colistin resistance noticed
after therapy)
1 (Case report) blood and urine 2011 yes (imipenem,
amikacin, colistin)
no [22]
Germany 128 (colistin resistance noticed
before therapy)
1 (Case report) skin and rectal swabs 2014 yes (colistin,
meropenem,
linezolid,
fosfomycin,
caspofungin)
no [27]
Brazil 8-64 7(35%) blood 2016 Vancomycin plus
specific therapy
Yes (Non-
specific to
colistin
resistance)
[25]
Table 1: Global reports of emergence of colistin resistant A. baumannii.
In Iran 13% of isolates from ICU were found to be resistant to
colistin, interestingly majority of isolates were also resistant to
imipenem [16]. In a recent study [24] from Romania colistin resistant
A. baumannii was isolated from bronchial suction from ICU. Another
study from Brazil [25] reported 7 out of 20 isolates were colistin
resistant in which 14 patients received therapy and 8 died during
therapy and vancomycin plus colistin therapy showed highest synergy
against colistin resistant isolates. There are various case reports from
Spain [26], France [22], Germany [27], Tunisia [28], Algeria [29] and
Japan [30] reporting colistin resistance, however, reports from
Germany and Japan showed colistin resistant A. baumannii were
isolated from international travelers. All above colistin resistance
reports have been summarized in Table 1.
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Conclusion
Colistin, a last resort antibiotic available to treat infections caused
by MDR Acinetobacter baumannii has received a lot of attention in last
decade. Notwithstanding, increased prevalence of colistin resistance in
Acinetobacter isolates has been reported throughout the world, albeit
with a great variability in the occurrence in different geographic areas.
The highest resistance rate was reported from Asia-Pacific followed by
Europe, Americas and Africa. Furthermore, resistance in Northern
Europe and Northern Asian countries has not been reported yet. There
are reports from almost all Mediterranean countries like Turkey,
Greece, Italy, Spain, Portugal, Egypt, Algeria and Tunisia. We could
also speculate due to immigration from developing countries to
Europe, there could have been transfer of colistin resistance. The
intrinsic mechanisms of resistance are related to a loss of LPS or/and
the PmrAB two-component system, additionally extrinsic colistin
resistance has been attributed to cause by mcr-1 genes carried on
plasmids. With the ever increasing rate of infections that A. baumannii
isolates can cause, the emergence of pan drug resistance signifies the
need to introduce strict preventive measures in hospitals and to use
novel agents or combination therapy. Although colistin resistance is
increasing continuously, clinicians should carefully detect risk factors
for its cause. Colistin resistance can be suppressed through reversing
efflux pump activity by using EPIs such as cyanide 3-
cholophenylhydrazone (CCCP), phenyl-arginine-β-naphthylamide
(PAβN), and 1-(1-naphthylmethyl)-piperazine (NMP) could be used.
Earlier, in vitro study has shown CCCP to significantly decrease MICs
of colistin resistance strains [41]; PAβN and NMP can partially
decrease MICs of colistin resistant A. baumannii. CCCP restore
negative charge of membrane through the disruption of proton motive
force. However, CCCP cannot be used clinically due to its intrinsic
cytotoxicity and needs further investigation to nullify it cytotoxicity or
develop new agents to protect the activity of colistin.
Acknowledgement
No funding received, no competing interests, and ethical approval is
not required.
References
1. Henry R, Vithanage N, Harrison P, Seemann T, Coutts S, et al. (2012)
Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii
responds to lipopolysaccharide loss through increased expression of
genes involved in the synthesis and transport of lipoproteins,
phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob
Agents Chemother 56: 59-69.
2. Gordon NC, Wareham DW (2010) Multidrug-resistant Acinetobacter
baumannii: mechanisms of virulence and resistance. Int J Antimicrob
Agents 35: 219-226.
3. Park YK, Peck KR, Cheong HS, Chung DR, Song JH, et al. (2009)
Extreme drug resistance in Acinetobacter baumannii infections in
intensive care units, South Korea. Emerg Infect Dis 15:1325-1327.
4. Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of
Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial
strategies. J Antimicrob Chemother 67: 1607-1615.
5. Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K,
et al. (2015) Rapid dissemination of colistin and carbapenem resistant
Acinetobacter baumannii in Central Greece: mechanisms of resistance,
molecular identification and epidemiological data. BMC Infect Dis 15:
559.
6. Guidelines for the management of adults with hospital-acquired (2005)
ventilator-associated, and healthcare-associated pneumonia. Am J Respir
Crit Care Med 171: 388-416.
7. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O'Hara JA, et al. (2014)
In vitro responses of Acinetobacter baumannii to two- and three-drug
combinations following exposure to colistin and doripenem. Antimicrob
Agents Chemother 58: 1195-1199.
8. Pristovsek P, Kidric J (1999) Solution structure of polymyxins B and E
and effect of binding to lipopolysaccharide: an NMR and molecular
modeling study. J Med Chem 42: 4604-4613.
9. Moffatt JH, Harper M, Adler B, Nation RL, Li J, et al. (2011) Insertion
sequence ISAba11 is involved in colistin resistance and loss of
lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents
Chemother 55: 3022-3024.
10. Soon RL, Nation RL, Cockram S, Moffatt JH (2011) Different surface
charge of colistin-susceptible and -resistant Acinetobacter baumannii
cells measured with zeta potential as a function of growth phase and
colistin treatment. J Antimicrob Chemother 66: 126-133.
11. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, et al. (2011)
Phosphoethanolamine modification of lipid A in colistin-resistant
variants of Acinetobacter baumannii mediated by the pmrAB two-
component regulatory system. Antimicrob Agents Chemother 55:
3370-3379.
12. Kim SH, Jia W, Parreira VR, Bishop RE, Gyles CL (2006)
Phosphoethanolamine substitution in the lipid A of Escherichia coli
O157 : H7 and its association with PmrC. Microbiology 152: 657-666.
13. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B,et al.
(2015) Detection of mcr-1 encoding plasmid-mediated colistin-resistant
Escherichia coli isolates from human bloodstream infection and
imported chicken meat, Denmark 2015. Euro Surveill 20.
14. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, et al. (2016) Emergence of
plasmid-mediated colistin resistance mechanism MCR-1 in animals and
human beings in China: a microbiological and molecular biological study.
Lancet Infect Dis 16: 161-168.
15. Ni W, Li Y, Guan J, Zhao J, Cui J, et al. (2015) Effects of Efflux Pump
Inhibitors on Colistin Resistance in Multidrug-Resistant Gram-Negative
Bacteria. Antimicrob Agents Chemother 60: 3215-3218.
16. Modarresi F, Azizi O, Shakibaie MR, Motamedifar M, Valibeigi B, et al.
(2015) Effect of iron on expression of efflux pump (adeABC) and quorum
sensing (luxI, luxR) genes in clinical isolates of Acinetobacter baumannii.
APMIS 123: 959-968.
17. Magnet S, Courvalin P, Lambert T (2001) Resistance-nodulation-cell
division-type efflux pump involved in aminoglycoside resistance in
Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother
45: 3375-3380.
18. Hejnar P, Kolar M, Hajek V (1999) Characteristics of Acinetobacter
strains (phenotype classification, antibiotic susceptibility and production
of beta-lactamases) isolated from haemocultures from patients at the
Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med 142:
73-77.
19. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, et al. (2006)
Heteroresistance to colistin in multidrug-resistant Acinetobacter
baumannii. Antimicrob Agents Chemother 50: 2946-2950.
20. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, et al. (2015)
Colistin-resistant Acinetobacter baumannii: beyond carbapenem
resistance. Clin Infect Dis 60: 1295-1303.
21. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, et al. (2014)
Spread of a carbapenem- and colistin-resistant Acinetobacter baumannii
ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp
Infect 86: 260-266.
22. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D (2011)
Acinetobacter baumannii resistant to colistin with impaired virulence: a
case report from France. J Infect Dis 204: 1146-1147.
23. Herrera ME, Mobilia LN, Posse GR (2011) Comparative evaluation of the
sensitivity of Acinetobacter to colistin, using the prediffusion and
Citation: Ahmed SS, Alp E, Hopman J, Voss A (2016) Global Epidemiology on Colistin Resistant Acinetobacter baumannii. J Infect Dis Ther 4:
287. doi:10.4172/2332-0877.1000287
Page 4 of 5
J Infect Dis Ther
ISSN:2332-0877 JIDT, an open access journal Volume 4 • Issue 4 • 1000287
42
minimum inhibitory concentration methods: detection of heteroresistant
isolates. Rev Argent Microbiol 43: 115-119.
24. Lazureanu V, Porosnicu M, Gandac C, Moisil T, Baditoiu L, et al. (2016)
Infection with Acinetobacter baumannii in an intensive care unit in the
Western part of Romania. BMC Infect Dis 16 Suppl 1: 95.
25. Leite GC, Oliveira MS, Perdigao-Neto LV, Rocha CK, Guimaraes T, et al.
(2016) Antimicrobial Combinations against Pan-Resistant Acinetobacter
baumannii Isolates with Different Resistance Mechanisms. PLoS One 11:
e0151270.
26. Lopez-Rojas R, Jimenez-Mejias ME, Lepe JA, Pachon J (2011)
Acinetobacter baumannii resistant to colistin alters its antibiotic
resistance profile: a case report from Spain. J Infect Dis 204: 1147-1148.
27. Gottig S, Gruber TM, Higgins PG, Wachsmuth M, Seifert H, et al. (2014)
Detection of pan drug-resistant Acinetobacter baumannii in Germany. J
Antimicrob Chemother 69: 2578-2579.
28. Baadani AM, Thawadi SI, El-Khizzi NA, Omrani AS (2013) Prevalence of
colistin and tigecycline resistance in Acinetobacter baumannii clinical
isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi
Med J 34: 248-253.
29. Al-Sweih NA, Al-Hubail MA, Rotimi VO (2011) Emergence of
tigecycline and colistin resistance in Acinetobacter species isolated from
patients in Kuwait hospitals. J Chemother 23: 13-16.
30. Tojo M, Mawatari M, Hayakawa K, Nagamatsu M, Shimada K, et al.
(2015) Multidrug-resistant Acinetobactor baumannii isolated from a
traveler returned from Brunei. J Infect Chemother 21: 212-214.
31. Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, et al. (2012) Clonal spread
of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J
Microbiol Immunol Infect 45: 37-42.
32. Lee SY, Shin JH, Park KH, Kim JH, Shin MG, et al. (2014) Identification,
genotypic relation, and clinical features of colistin-resistant isolates of
Acinetobacter genomic species 13BJ/14TU from bloodstreams of patients
in a university hospital. J Clin Microbiol 52:931-939.
33. Batarseh A, Al-Sarhan A, Maayteh M, Al-Khatirei S, Alarmouti M (2016)
Antibiogram of multidrug resistant Acinetobacter baumannii isolated
from clinical specimens at King Hussein Medical Centre, Jordan: a
retrospective analysis. East Mediterr Health J 21: 828-834.
34. Taneja N, Singh G, Singh M, Sharma M (2011) Emergence of tigecycline
& colistin resistant Acinetobacter baumanii in patients with complicated
urinary tract infections in north India. Indian J Med Res 133: 681-684.
35. Jaidane N, Cherifa C, Messaoudi A, Boujaafar N, Bouallegue O (2015)
Colistin-resistant Acinetobacter baumannii: a case report and literature
review. Reviews in Medical Microbiology 26: 78-83.
36. Bakour S, Olaitan AO, Ammari H, Touati A, Saoudi S, et al. (2015)
Emergence of Colistin- and Carbapenem-Resistant Acinetobacter
baumannii ST2 Clinical Isolate in Algeria: First Case Report. Microb
Drug Resist 21: 279-285.
37. Al-Agamy MH, Khalaf NG, Tawfick MM, Shibl AM, El Kholy A (2014)
Molecular characterization of carbapenem-insensitive Acinetobacter
baumannii in Egypt. Int J Infect Dis 22: 49-54.
38. Moisoiu A, Ionită M, Sârbu L, Stoica C, Grigoriu L (2014) Antibiotic
resistance of Acinetobacter baumannii strains isolated from clinical
specimens in the "Marius Nasta" Pneumology Institute, Bucharest.
Pneumologia 63: 109-111.
39. Quinteira S, Grosso F, Ramos H, Peixe L (2007) Molecular epidemiology
of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter
baumannii isolates carrying plasmid-mediated OXA-40 from a
Portuguese hospital. Antimicrob Agents Chemother 51: 3465-3466.
40. Cikman A, Gulhan B, Aydin M, Ceylan MR, Parlak M, et al. (2015) In
vitro Activity of Colistin in Combination with Tigecycline against
Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from
Patients with Ventilator-Associated Pneumonia. Int J Med Sci 12:
695-700.
41. Park YK, Ko KS (2015) Effect of carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) on killing Acinetobacter baumannii by
colistin. J Microbiol 53: 53.
 
Citation: Ahmed SS, Alp E, Hopman J, Voss A (2016) Global Epidemiology on Colistin Resistant Acinetobacter baumannii. J Infect Dis Ther 4:
287. doi:10.4172/2332-0877.1000287
Page 5 of 5
J Infect Dis Ther
ISSN:2332-0877 JIDT, an open access journal Volume 4 • Issue 4 • 1000287
43
Chapter 6 
 
Establishing Molecular Microbiology Facilities in Developing Countries 
 
 
 
 
 
 
 
 
 
44
Journal of Infection and Public Health (2015) 8, 513—525
REVIEW
Establishing  molecular  microbiology
facilities  in  developing  countries
Salman  S.  Ahmeda,b,∗,  Emine  Alpa,b,
Aysegul  Ulu-Kilica,  Mehmet  Doganaya
a Department  of  Infectious  Diseases,  Faculty  of  Medicine,  Erciyes  University,  Kayseri,
Turkey
b Department  of  Molecular  Microbiology,  Genome  and  Stem  Cell  Center,
Erciyes Univeristy,  Kayseri,  Turkey
Received  26  November  2013;  received  in  revised  form  10  March  2015;  accepted  3  April  2015
KEYWORDS
Developing  country;
Molecular  technique;
Molecular  microbiology
laboratory
Summary  Microbiology  laboratories  play  an  important  role  in  epidemiology  and
infection  control  programs.  Within  microbiology  laboratories,  molecular  microbiol-
ogy  techniques  have  revolutionized  the  identiﬁcation  and  surveillance  of  infectious
diseases.  The  combination  of  excellent  sensitivity,  speciﬁcity,  low  contamination  lev-
els  and  speed  has  made  molecular  techniques  appealing  methods  for  the  diagnosis
of  many  infectious  diseases.  In  a  well-equipped  microbiology  laboratory,  the  facility
designated  for  molecular  techniques  remains  indiscrete.  However,  in  most  develop-
ing  countries,  poor  infrastructure  and  laboratory  mismanagement  have  precipitated
hazardous  consequences.  The  establishment  of  a  molecular  microbiology  facility
within  a  microbiology  laboratory  remains  fragmented.  A high-quality  laboratory
should  include  both  conventional  microbiology  methods  and  molecular  microbiology
techniques  for  exceptional  performance.  Furthermore,  it  should  include  appropriate
laboratory  administration,  a  well-designed  facility,  laboratory  procedure  standard-
ization,  a  waste  management  system,  a  code  of  practice,  equipment  installation  and
laboratory  personnel  training.  This  manuscript  lays  out  fundamental  issues  that  need
to  be  addressed  when  establishing  a molecular  microbiology  facility  in  developing
countries.
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Introduction
Microbiology  laboratories  play  an  important  role  in
the management  of  infectious  diseases  in  terms
of national  or  global  epidemiology.  In  the  twenty-
ﬁrst century,  molecular  microbiology  techniques  for
epidemiology  and  infection  control  programs  have
become  more  demanding.  Molecular  techniques
in high-quality  clinical  microbiological  laboratories
are  routinely  used  to  make  clinical  decisions  on  the
basis of  how  and  when  to  treat  patients.  Molecu-
lar techniques  are  also  useful  for  monitoring  the
effectiveness  of  therapeutic  regimes  and  identi-
fying potential  resistant  strains  that  may  impact
a long  term  treatment  program.  The  manage-
ment and  control  of  infectious  diseases  requires
accurate diagnosis  and  knowledge  of  pathogen
distributions. The  inclusion  of  molecular  typing
techniques  for  almost  all  infectious  disease  agents
within  a  clinical  microbiology  laboratory  provides
a detailed  assessment  of  any  given  strain’s  inter-
relationships,  and  thus  can  identify  the  source
of the  organism  [1]. Almost  all  epidemiologi-
cal studies  depend  on  molecular  techniques  for
the identiﬁcation,  characterization  and  genetic
typing of  microbes.  Nevertheless,  the  lack  of  infra-
structure  for  infectious  disease  management  in
developing  countries  has  been  blamed  for  the
uncontrollable  rates  of  infection  and  mortality
[2,3].  In  some  resource-limited  countries,  sentinel
hospitals  lack  even  basic  microbiology  laboratory
facilities [4]. In  other  regions,  laboratories  have
all of  the  requisite  reagents  and  instruments  but
lack skilled  staff.  Other  laboratories  can  amplify
DNA but  are  unable  to  report  the  necessary  results
in time.  Furthermore,  many  laboratories  neglect
accreditation,  quality  assurance  and  quality  control
programs.  For  these  reasons,  infectious  diseases
in most  developing  countries  remain  unknown
and uncharacterized  [5].  The  Centers  for  Disease
Control  (CDC)  has  initiated  various  strategies  in
developing  countries  that  require  clinical  micro-
biology  laboratories  to  provide  accountable  data
as part  of  an  active  surveillance  of  infectious
diseases. However,  clinical  microbiology  labora-
tories  have  not  been  recognized  as  a priority
by government  bodies  in  developing  countries.
As mentioned  above,  part  of  the  problem  is
associated with  a  lack  of  skilled  laboratory  per-
sonnel  and  prohibitive  laboratory  maintenance
costs where  resources  are  available  but  inappropri-
ately used  [6]. This  manuscript  discusses  the  role
of molecular  techniques  in  clinical  microbiology
and epidemiology  and  the  various  issues  required
to establish  molecular  laboratories  in  developing
countries.
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The role of molecular techniques in
clinical microbiology and infection
control programs
Conventionally,  the  function  of  a  clinical  microbiol-
ogy laboratory  is  to  identify  various  pathogens  using
direct examination  of  microbes  and  culture-based
methods. At  present,  nucleic  acid  ampliﬁcation
and DNA  probes  are  useful  for  the  characteriza-
tion of  microbes  because  cultured-based  methods
are insufﬁcient,  expensive  and  tedious.  Typi-
cally, nonampliﬁed  DNA  probe-based  methods  are
suitable for  in  situ  hybridization  of  organisms
when the  location  and  distribution  are  ascer-
tained, including  slow  growing  microbes  such  as
Neisseria  gonorrhoeae  and  Mycobacterium  tuber-
culosis.  Pathogenic  dimorphic  fungi  have  also  been
detected  radiometrically.  Many  DNA  probe  methods
are commercially  available  for  the  identiﬁcation
of various  microbial  species,  such  as  Chlamydia
trachomatis, Legionella  pneumophila,  Trichomonas
vaginalis, Candida  species,  and  human  papillo-
mavirus (HPV).  In  addition  to  the  beneﬁt  of the
conﬁrmation  of  culture  methods,  DNA  probes  are
useful for  identifying  enterotoxin-producing  strains
of Escherichia  coli  because  these  strains  are  bio-
chemically  similar  to  other  non-enterotoxigenic
E. coli.  Although  traditional  DNA  probe  methods
have a  lower  sensitivity  than  nucleic  acid  ampliﬁ-
cation  techniques,  DNA  probes  are  useful  for  the
direct  identiﬁcation  of  clinical  specimens  in  cer-
tain situations.  For  example,  DNA  probes  are  used
to identify  group  A  streptococci  in  strep  throat
infections and  C.  trachomatis  or  HPV  in  cervical
infections. Furthermore,  the  high  level  sensitiv-
ity of  nucleic  acid  ampliﬁcation  makes  it  an  ideal
choice  for  the  direct  detection  of  specimens.  How-
ever, expensive  molecular  procedures  should  not
replace cost-effective  conventional  methods  that
are rapid,  sensitive  and  candid.  For  instance,  the
use of  shell  vials  and  monoclonal  antibodies  for
the diagnosis  of  cytomegalovirus  viremia  in  an
immunosuppressed  bone  marrow  transplant  recip-
ient is  an  excellent  method  with  high  speciﬁcity
and sensitivity  and  results  that  are  available  within
16 hours.  Thus,  it  would  be  unfavorable  to  disre-
gard this  method  and  replace  it  with  costlier  nucleic
acid ampliﬁcation  methods  without  additional  doc-
umentation  of  the  substantial  beneﬁts  of  the  latter
methods.
When considering  the  correct  molecular  method
to be  used  in  the  laboratory,  careful  and  ﬁrm
decision-making  should  be  directed  toward  the
potential  beneﬁts  of  modern  methodology.  Deci-
sions should  not  be  made  based  solely  on
the  cost-effectiveness  of  the  molecular  method.
Instead, the  impact  of  the  method  on  the  clini-
cal practice  and  patient  management  should  also
be considered.  For  instance,  direct  detection  of
methicillin-resistant  Staphylococcus  aureus  and  M.
tuberculosis  in  a patient’s  specimens  would  result
in quicker  patient  isolation,  better  targeted  ther-
apy and  overall  cost  savings.  In  other  situations,
microbes can  be  extremely  fastidious,  difﬁcult  to
culture and  hazardous  to  laboratory  staff.  These
microbial  samples  are  often  sent  to  referral  cen-
ters; however,  fragile  microbes  could  lose  their
viability, become  overgrown  or  even  become  con-
taminated  during  the  transferal  process.  Often,  a
sample with  a limited  volume  submitted  to  the
laboratory  becomes  impossible  to  culture.  In  such
cases, accurate  usage  of  the  sample  is  needed  to
culture all  pathogens.  In  many  resource  limited
countries, biosafety  level  3  laboratories  may  not  be
available or  may  be  economically  inappropriate  to
culture pathogenic  microbes  [7]. Molecular  tech-
niques  have  resolved  many  of  these  problems  by
identifying  microbes  more  rapidly  and  accurately
than conventional  techniques.  For  instance,  more
than 100  genotypes  of  HPV  have  been  found  using
DNA sequence  heterogeneity  as  the  basis  for  inves-
tigation.
It is  important  to  remember  that  despite
their sensitivity,  accuracy  and  speed,  nucleic  acid
ampliﬁcation  methods  cannot  totally  replace  con-
ventional  culture  and  serologic  methods  because
nucleic acid  ampliﬁcation  and  conventional  meth-
ods produce  different  results.  Nucleic  acid  ampli-
ﬁcation  methods  detect  the  presence  of  DNA  or
RNA in  a  particular  specimen,  but  they  cannot
demonstrate the  viability  of  an  organism  or  deter-
mine whether  the  organism  is  part  of  the  infectious
process. Furthermore,  nucleic  acid  ampliﬁcation
methods are  prone  to  errors,  and  large  amounts  of
ampliﬁed  products  can  lead  to  momentous  cross-
contamination  and  cause  false  positive  results.
Conventional methods  such  as  culture-based  tech-
niques validate  the  viability  of  an  organism,  and
quantiﬁcation  of  the  antibody  titer  strongly  sug-
gests its  involvement  as  part  of  the  infectious
process. Commercial  DNA  probes  have  brought
molecular techniques  into  the  ﬁeld  of  clinical
microbiology and  have  been  used  for  several  years.
Today, most  of  the  procedures  have  been  stan-
dardized  and  are  frequently  simpler  than  target
ampliﬁcation  assays.  Additionally,  the  advent  of
the synthetic  short  oligonucleotide  DNA  probe  has
reduced the  time  required  for  hybridization  assays.
The niche  for  DNA  probe  technology  in  clinical
microbiology appears  to  be  in  situ  hybridization
for tissue  specimens  and  culture  conformation  of
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slow-growing  microbes.  Although  DNA  probes  are
more expensive  than  other  biochemical  tests,  their
rapid turnaround  time  can  be  translated  into  overall
savings by  providing  a  timely  diagnosis.  Using  stan-
dardized  methodology,  DNA  probes  can  broaden  the
various types  of  pathogens  that  a  microbiology  lab-
oratory can  routinely  identify.  The  three  different
formats commonly  used  today  are  solution-phase
hybridization,  in  situ  hybridization  and  solid-phase
hybridization.  At  present,  the  nucleic  acid  ampli-
ﬁcation  technique  is  routinely  used  in  numerous
microbiology laboratories.  This  technique  improves
the sensitivity  of  assays  based  on  nucleic  acids  and
can simplify  assays  by  automating  and  incorporating
non-radioactive  detection  formats.  The  technology
behind  the  nucleic  acid  ampliﬁcation  method  is
diverse and  in  constant  ﬂux.  There  are  three  dif-
ferent categories:  (i)  target  ampliﬁcation  by  PCR,
which relies  on  self-sustaining  sequence  replica-
tion or  strand  disruption  ampliﬁcation;  (ii)  probe
ampliﬁcation  including  a  ligase  chain  reaction;  and
(iii) signal  ampliﬁcation.  All  of  these  techniques
are currently  used  to  varying  degrees,  and  many
have been  cleared  by  the  American  Food  and  Drug
Administration (FDA).  A  detailed  account  of  all  of
the molecular  methods  used  in  clinical  microbiology
laboratories is  beyond  the  scope  of  this  manuscript.
However, some  commercially  available  molecular
assays for  various  infectious  agents  are  discussed  in
Table  1.
Molecular  typing  techniques  have  greatly  facil-
itated  epidemiologists  and  infection  control  spe-
cialists.  The  main  purpose  of  an  infection  control
program is  to  identify  possible  infection  problems
and monitor  infection  trends.  Infection  control  pro-
grams depend  on  cooperation  from  microbiology
laboratories,  which  must  provide  easy  access  to
high-quality  data  and  guide  the  use  of  resources
for epidemiological  purposes.  Furthermore,  labo-
ratory ﬁndings  are  used  to  support  epidemiologic
evidence of  the  spread  of  common  microbes  and
determine  the  modes  of  transmission  [8].  Molecu-
lar typing  techniques  have  been  successfully  used  in
microbiology  laboratories  for  the  epidemic  surveil-
lance of  various  pathogens  [9]. Several  molecular
typing methods  have  been  proposed,  such  as  pulse
ﬁeld gel  electrophoresis  (PFGE),  ribotyping  and
nucleic acid  ampliﬁcation-based  typing  schemes.
Currently,  pulse  ﬁeld  gel  electrophoresis  is  widely
used  for  the  molecular  typing  of  various  bacte-
rial species.  This  technique  allows  investigators
to separate  larger  pieces  of  DNA  using  restriction
enzymes and  has  been  used  to  characterize  bac-
terial species  from  different  geographical  regions.
This technique  has  better  discriminating  power
than other  typing  schemes,  such  as  ribotyping  and
multi  locus  sequence  typing  based  on  DNA  ampliﬁ-
cation reactions.  The  results  can  be  visualized  with
a dendrogram  generated  by  matrix  pair  differences
between the  electrophoretic  types.  Despite  PFGE
being considered  by  analogy  as  a ‘gold  standard’  by
many investigators,  many  strains  cannot  be  typed
due to  degradation  of  the  DNA  in  the  gel.  More-
over, the  apparatus  and  the  specialized  chemicals
are expensive,  time  consuming  and  require  skilled
technicians.  PFGE  has  a  lower  resolution  power
than multi  locus  sequence  typing  (MLST),  which  is
a nucleic  acid  ampliﬁcation-based  method,  and  as
such it  is  widely  accepted  as  ‘the  typing  success
of the  decade’  because  it  can  be  applied  to  bacte-
ria and  other  microbes.  This  technique  can  be  used
to study  the  evolutionary  relationships  between
bacteria due  to  its  high  discriminatory  power.  MLST
is portable,  and  unlike  PFGE  its  results  can  be  use-
fully shared  between  laboratories.  A  huge  number
of microbes  have  been  studied  under  these  two
schemes  [10]. Moreover,  MLST  requires  a  normal
thermocycler for  ampliﬁcation  that  can  also  be  used
for many  other  direct  detection  assays  and  for  the
identiﬁcation  of  various  genes,  while  MLST  requires
an expensive  nucleic  acid  sequencing  apparatus.
However, post-ampliﬁcation  products  can  also  be
sequenced using  commercially  available  sequenc-
ing apparatuses  by  paying  for  just  the  cost  of
the reaction.  To  date,  various  molecular  typing
techniques have  been  used  to  map  various  epi-
demiological traits.  However,  the  selection  of  these
techniques  depends  on  the  aim  and  objectives  of
the particular  epidemiological  study.  This  is  espe-
cially true  in  developing  countries  or  regions  where
resources  are  limited  and  skilled  personnel  are  in
demand.
New molecular technologies
Currently,  the  application  of  nucleic  acid  ampliﬁ-
cation  and  other  molecular  platforms  is  limited  to
large laboratories  and  referral  centers.  The  abil-
ity to  use  these  techniques  efﬁciently  is  another
important factor  that  determines  how  large  a  role
these techniques  will  play  in  an  average  microbiol-
ogy laboratory.  There  is  a  growing  need  for  newer
technologies that  are  rapid,  cost  effective  and  suit-
able for  low  resource  countries.
Real-time droplet PCR
Because  PCR  requires  thermal  cycling,  it  is typically
performed  in  a  bench  top  unit.  This  process  is  slow,
expensive,  error-prone  due  to  contamination  and
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requires  a  large  amount  of  sample  to  perform  the
reactions.  Utilizing  the  concept  of  both  spatial  and
temporal  microﬂuidic  PCR,  droplet-based  microﬂu-
idic PCR  formats  are  emerging  as  alternatives  to
single-phase  PCR.  Droplet  PCR  formats  have  many
advantages,  such  as  low  reagent  usage,  faster
thermal cycling  and  limited  interactions  of  DNA
and polymerase  with  the  channel  walls.  Carryover
contamination can  be  reduced  using  these  for-
mats,  resulting  in  high  throughput  and  sensitivity.
Droplets are  discrete  small  volumes  that  can  be
adapted  for  parallel  ampliﬁcation  in  small  concen-
trations.  There  are  a  number  of  pressure-driven
ﬂow systems  that  use  microdroplets,  nanodroplets,
and picodroplets  to  perform  both  PCR  and  reverse
transcriptase PCR.  Many  commercially  available
products based  on  real-time  droplet  PCR  have  var-
ious applications,  such  as  absolute  quantiﬁcation,
rare gene  identiﬁcation,  genomic  alterations,  and
single cell  analysis.  A  few  studies  have  reported  the
use of  droplet  PCR  for  the  diagnosis  of  infectious
disease agents  such  as  C.  trachomatis  (73.3%  sen-
sitivity)  and  inﬂuenza  subtypes  (96%  sensitivity  and
100% speciﬁcity).  This  technique  can  be  adopted
in small  clinics  and  average  laboratories  [11,12],
especially in  resource  limited  countries.
Mass spectrometry
Mass  spectrometry  (MS)  was  recently  introduced
as a  new  diagnostic  technique  in  clinical  micro-
biology with  the  ﬁrst  successful  application  in
detection  and  sequence-based  identiﬁcation  of
PCR products.  Based  on  MS,  matrix-assisted  laser
desorption/ionization  (MALDI)  coupled  with  time
of light  (TOF)  allows  the  analysis  of  various
biomolecules  in  microbes.  This  method  is  very
effective and  requires  less  intense  sample  prepa-
ration  because  the  matrix  is  less  susceptible  to
interference  from  salts  and  detergents.  MALDI-TOF
is an  extremely  useful  technique  for  the  identi-
ﬁcation of  many  microbial  species  because  the
major  mass  proﬁle  is  generated  from  ribosomal  pro-
teins that  align  perfectly  with  current  taxonomic
classiﬁcations.  For  epidemiological  typing  studies
of bacterial  isolates,  mass  peaks  that  are  spe-
ciﬁc to  a  given  strain  can  easily  be  identiﬁed  and
used to  develop  a  binary  typing  system.  Further-
more, substantial  resistance  mechanisms  can  also
be identiﬁed.  Cellular  modiﬁcations  under  the  inﬂu-
ence of  antibiotics  can  also  be  detected,  as  was
recently  demonstrated  by  the  interaction  between
Candida  albicans  cells  and  ﬂuconazole  and  Candida
and Aspergillus  species  and  caspofungin.  Addition-
ally, MS  can  be  used  to  identify  PCR  products
derived from  resistance  genes.  The  iPLEX  MassArray
developed  by  Sequenom  is  a very  good  example
of this  extensible  technology.  However,  there  are
many opposing  issue  with  this  diagnostic  MST.  The
assays typically  require  104—105 cells,  which  are
infrequently detected  in  patient  specimens  except
urinary  tract  infections.  Moreover,  the  equipment
is very  expensive  and  needs  expensive  maintenance
[13].
Nucleic acid sequencing
DNA  sequencing  is  already  used  in  many  diagnostic,
typing and  research  studies  and  is  particularly  use-
ful for  bacterial  identiﬁcation  based  on  16S  rRNA
sequences.  Previously,  this  method  was  employed
to identify  short  nucleotide  sequences  of  PCR-
ampliﬁed products.  However,  with  advances  in
technology  it  now  is  able  to  identify  complex
genome mixtures  of  bacteria  in  a  process  called
‘metagenomics’ and  can  generate  complete  cat-
alogues of  genomic  components  of  the  bacterial
species present  in  a variety  of  clinical  specimens.
Although at  present,  it  remains  unclear  whether
this technology  is  suitable  for  routine  usage  in
microbiology  laboratories,  metagenomics  is  essen-
tial for  understanding  the  effects  of  antibiotic
treatment of the  human  microbiome  as  a whole.
Furthermore, next-generation  sequence  analysis
can facilitate  testing  of  host  susceptibility  toward
infection  and  colonization  if  the  high  cost  of  the
apparatus  is  considered  to  be  a subsidiary  issue  for
the circumstances  of  each  individual  case.  This  cur-
rent basic  research  development  will  become  more
common  in  diagnostic  laboratories  in  coming  years
[14].
Microbial volatile organic compound
detection
Microbial  volatile  organic  compounds  (MVOCs)  are
deﬁned as  a variety  of  compounds  formed  during
metabolism in  bacteria  and  fungi.  To  date,  more
than 200  different  MVOCs  have  been  identiﬁed,
and the  diagnostic  relevance  of  MVOCs  has  been
described  in  the  literature.  However,  difﬁculties  in
the reproducibility  of  diagnostic  assays  and  the  con-
centrations  of  MVOCs  cannot  be  overlooked  [15].
The most  widely  used  MVOC  detection  technique  is
the micro-weighing  technique  using  vibration  meth-
ods, gas  chromatography  and  metal  chip  electrical
conductivity.  This  technology  has  been  developed
based on  the  design  of  a system  that  allows  the
kinetic measurement  of  MVOC  production  by  grow-
ing bacteria;  indeed,  several  bacterial  species  are
identiﬁable  on  the  basis  of  their  MVOC  production
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proﬁle.  For  instance,  a  study  was  conducted  in
which the  diagnostic  speciﬁcities  varied  from  100%
for C.  difﬁcile  to  67%  for  Enterobacter  cloacae  [16].
This ﬁnding  suggests  that  the  diagnosis  capability  of
this technique  can  be  developed  in  the  future  for
use by  clinical  microbiology  laboratories.
Raman spectroscopic analysis
The  most  evident  contribution  of  spectroscopy  to
clinical microbiology  has  been  in  microbial  epi-
demiology.  In  recent  years,  Raman  spectroscopic
analysis (RSA)  has  been  validated  for  the  bacterial
typing of  different  species.  Although  RSA  has  been
proposed  to  be  capable  of  distinguishing  virtually
all bacterial  species,  deﬁnitive  data  are  missing.
RSA is  a  label-free,  optical  technology  based  on  the
non-elastic  scattering  of  light  by  the  molecules.  The
change in  wavelength  is molecule-speciﬁc  and  can
be displayed  in  a  Raman  spectrum.  These  changes
can be  seen  as  spectroscopic  ﬁngerprints  and  can
be used  to  visualize  the  comprehensive  molecular
composition. Several  studies  concluded  decisively
that the  typing  of  different  strains  belonging  to
a single  species  can  be  performed  appropriately.
The molecular  typing  of  various  species  such  as
E. coli,  Pseudomonas  aeruginosa, Staphylococcus,
and Klebsiella  pneumoniae  produced  similar  results
that were  equal  in  quality  to  other  gold  standard
techniques [17].
Nanoparticles
A  variety  of  methods  have  been  introduced  into
clinical microbiology  over  the  course  of  the  last
decade.  These  methods  clearly  meet  some  diag-
nostic standards  and  development  is  continuing.
Moreover, many  new  technologies  are  making  their
way into  diagnostic  microbiology,  such  as  cell-based
biosensors  in  the  area  of  ‘nanodiagnostics’.  This
technology  uses  cells  as  biochemical  detectors  with
high sensitivity  and  speciﬁcity.  Furthermore,  there
has been  an  emergence  of  ‘theranostics’,  which
appropriately combines  attributes  of  diagnostics
and therapy  to  ﬁght  against  infection.  Recently,  sil-
ver nanoparticles  (a  noble  metal  known  to  exhibit
strong toxic  effects  against  microbes  and  less  tox-
icity to  humans)  have  been  tested.  A  recent  study
[18]  using  electron  microscopy  revealed  ‘pits’  in  the
cell walls  of  E.  coli  and  other  microbes  that  were
caused by  the  accumulation  of  silver  nanoparticles.
These ‘pits’  resulted  in  the  alteration  of  membrane
morphology and  increased  membrane  permeability,
leading to  cell  death.  Thus,  this  study  clearly  exem-
pliﬁes the  role  of  nanoparticles  in  circumventing
the forthcoming  threat  of  bacterial  infections.
Although  there  are  numerous  beneﬁts  of  molec-
ular techniques,  the  advantages  of  many  conven-
tional methods  should  not  be  overlooked.  Currently,
a well-equipped  microbiology  laboratory  should
have both  reliable  conventional  methods  and  new
molecular  techniques,  and  staff  should  focus  on
issues such  as  cost,  performance,  durability  and
maintenance.
Laboratory facilities in developing
countries
The  quality  of  the  laboratory  service  depends
upon various  fundamental  strategies,  including
adequately trained  laboratory  staff,  management
of the  physical  laboratory  infrastructure,  good  lab-
oratory practices,  strict  quality  control,  quality
assurance  programs,  and  investment  into  new  and
improved technology  [19]. However,  in  many  devel-
oping countries  there  is  scarcity  of  basic  policies
required for  a  quality  functional  laboratory.  Labo-
ratory settings  without  proper  infrastructure  pose
the greatest  challenge  for  adequate  performance.
A lack  of  clean  water  and  inadequate  supply  of  elec-
tricity  and  cold  storage  immensely  limit  the  quality
of laboratory  procedures  [20].
Laboratory management
The  management  of  a  high-quality  clinical  micro-
biology  laboratory  is  crucial  for  the  control  of
hospital  and  community  acquired  infections.  Due
to the  lack  of  expertise  in  managing  clinical  micro-
biology  laboratories  in  developing  countries,  there
should be  international  guidance  or  training  for
the staff;  if  possible,  training  programs  should  be
conducted  by  high-quality  laboratories  from  devel-
oped countries.  Careful  review  of  the  available
resources, foundation  and  facilities  would  expedite
the available  support  required.  Furthermore,  vis-
iting various  established  laboratories  that  perform
identical  work  can  provide  important  information
[20]. Evaluation  and  accreditation  of  the  labora-
tory is also  important;  however,  this  process  is
dependent  on  the  overall  cost  and  available  fund-
ing. Laboratory  administration  should  take  care  of
their internal  staff  and  external  communication  sys-
tems. The  staff  should  receive  medical  evaluation
in case  of  emergency,  and  medical  records  main-
tenance should  be  performed  appropriately  [7].
Effective communication  between  the  laboratory
and health  care  providers  should  be  supported,
especially with  the  physician.  Because  the  shared
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information  is  both  qualitative  and  analytical,  ade-
quate provision  for  bidirectional  interactions  should
be maintained.  Telephone,  email,  facsimile  and
central laboratory  information  systems  are  useful
for documentation  [21].
Laboratory networking systems
Networking  between  laboratories  may  increase
infection surveillance  within  a  huge  geographi-
cal region.  The  WHO  supports  the  establishment
of national  networks  for  the  regular  exchange  of
information  and  proper  support  for  the  labora-
tory. However,  only  a  few  countries  have  national
and international  laboratory  networks  [22]. The
establishment  of  an  integrated  laboratory  system
is very  important  to  combat  many  infectious  dis-
eases. However,  integrated  systems  are  ﬁnancially
neglected  in  developing  countries.  Strengthening
laboratory systems  in  developing  countries  requires
effective  strategic  plans  involving  (a)  legal  and  pol-
icy framework,  (b)  institutional  and  management
framework, (c)  human  resources,  (d)  laboratory
quality management,  (e)  evaluation  and  moni-
toring,  (f)  maintenance  of  equipment,  and  (g)
laboratory  structure  and  design  [23].
Laboratory biosafety and risk
assessment
Clinical  microbiology  laboratories  expose  their  staff
and the  public  to  various  clinical  samples,  which
may  include  various  biohazards  such  as  infectious
diseases. Therefore,  it  is  important  to  develop  a
biosafety  management  program  or  operational  plan
for the  laboratory  with  regular  training  schemes,
thereby ensuring  the  use  of  standard  practices  and
procedures.  Laboratory  facilities  are  designed  to
meet certain  biosafety  levels  that  have  designated
constructional designs,  containment  accessibili-
ties, equipment,  operations  and  procedures  that
are employed  for  risky  biological  agents.  Sample
collection, transportation,  handling,  labeling  and
identiﬁcation  should  be  performed  according  to
WHO recommendations  [24]. A  laboratory  biosafety
plan should  be  maintained  to  reduce  any  accidental
release of  biohazardous  material.  The  compre-
hensive plan  should  include  working  guidelines,
primary care  designs  such  as  protective  equipment
and biosafety  cabinets,  and  secondary  care  designs
including  laboratory  facilities.  Furthermore,  the
biosafety  plan  should  promote  the  prevention  of
laboratory-associated  infections  and  environmental
protection.  A  biosafety  committee  should  be  estab-
lished to  gauge  the  success  of  the  biosafety  plan  by
implementing  and  enforcing  laboratory  protocols
and encouraging  strict  adherence  to  safety  guide-
lines. Because  the  identity  of  infectious  agents
remains unknown  during  the  initiation  of  microbial
investigations, biosafety  level-2  is  recommended
for clinical  microbiology  laboratories  [25,26].
Laboratory accreditation
Medical  laboratories  are  regulated  by  government
bodies and  strengthened  by  the  standards  validated
by other  professional  organizations.  Accreditation
is an  assessment  process  performed  by  an  autho-
rized body  to  ensure  quality  control  and  the
assurance of  the  laboratories.  This  process  pro-
vides formal  recognition  that  the  laboratory  can
perform  quality  experiments.  Laboratories  test-
ing human  samples  for  the  diagnosis,  prevention
or treatment  of  diseases  are  within  the  scope
of the  assessment  [27].  All  of  the  accredita-
tion regulations  are  developed  through  consensus,
collaboration and  consultation  of  health  care
professionals and  health  care  authorities.  The
laboratory  standards  are  monitored  by  on-site
inspection, management  requirements  for  patient
testing,  and  follow-up  actions.  Although  there  are
differences  in  accreditation  service  procedures
and programs,  the  overall  assessment  remains
the same  [28]. The  international  organization
for standardization  (ISO)  is  a global  organiza-
tion for  national  standards  that  is  comprised  of
140 members  across  the  globe.  The  International
Accreditation  Forum  (IAF)  and  the  International
Laboratory Accreditation  Cooperation  (ILAC)  deal
speciﬁcally  with  laboratories.  The  ILAC  commis-
sions tasks  local  bodies  such  as  the  Asia  Paciﬁc
Laboratory Accreditation  Cooperation  (APLAC)  in
Asia using  ISO  standards  [29]. The  standard  guide-
lines for  regulating  quality  laboratory  management
are included  in  ISO  15189:2007,  which  can  be
obtained from  the  ISO  website  (http://www.
iso.org/iso/catalogue  detail?csnumber=42641).
Laboratory design
The  establishment  of  a  clinical  microbiology  lab-
oratory in  low-resource  countries  requires  the
following  strategies:  (a)  requirement  for  physical
infrastructure,  (b)  various  assays,  (c)  supplemen-
tation of reagents,  (d)  provision  of  equipment
and maintenance,  and  (e)  dedicated  working
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stations.  In  developing  countries,  these  key  points
are usually  overlooked  due  to  other  issues.  The
main requirement  for  designing  a  microbiology
laboratory  is  a  clean  and  well-controlled  environ-
ment [30].  Surfaces  contaminated  with  dust  and
aerosols  and  humid  areas  will  be  hazardous  for
the microbiological  procedures.  Mechanical  ven-
tilation  systems  providing  inward  ﬂow  of  air  are
recommended  to  provide  containment  zones  with
increased  negative  pressure.  The  reliable  supply
and  maintenance  of  gas  and  a  standby  electricity
generator are  preferred.  Special  attention  should
be paid  to  the  huge  volume  of  microbes,  overcrowd-
ing equipment,  infestation  and  unauthorized  entry.
Other laboratory  features  must  also  be  addressed,
such as  dead  space  areas  with  no  airﬂow  and  low
ceilings that  prevent  the  exclusion  of  contamina-
tion during  microbiology  procedures  [26]. Waste
pipes, drainage,  and  ventilation  systems  manag-
ing contaminated  material  should  be  maintained
efﬁciently. Even  building  material,  such  as  a leak-
ing roof  that  causes  moisture,  could  be  sources  of
contamination.  The  location  of  heavy  equipment
should facilitate  the  cleaning  of  the  laboratory
walls and  ﬂoors  or  may  be  placed  on  mobile
benches [31]. Illumination  should  be  appropriate
for the  safe  conduct  of  laboratory  work.  Storage
should be  appropriate  for  all  supplies,  reagents,
hazardous chemicals  and  radioactive  materials.  A
holding zone  for  laboratory  garments  such  as  aprons
and lab  coats  should  be  placed  outside  or  possibly
at the  entrance  of  the  laboratory.  Hand  hygiene
basins should  be  provided  at  the  entry  and  exit
points with  alcohol  rubs.  Eating  and  drinking  should
not be  permitted  within  the  laboratory  because
these activities  may  serve  as  the  main  source
of contamination.  If  possible,  every  room  in  the
laboratory  should  have  hand  glove  stations  and
medical  waste  collection  bags.  Doors  should  have
vision panels,  be  self-closing  and  have  ﬁre  rat-
ings [32].  Although  there  is  no  special  guideline
for the  manner  in  which  the  space  in  a labo-
ratory is  used,  an  area  of  350  ft/person  within
the laboratory  would  enable  worker  safety  [26].
The high  risk  of  specimen—specimen  contact  when
performing  PCR-based  assays  requires  specialized
set-up. Four  different  physically  separated  work-
ing areas  are  recommended,  including  an  area  for
reagent  preparation,  PCR  master  mix  preparation,
nucleic acid  processing  and  an  ampliﬁcation  area.
All of  these  working  spaces  should  be  kept  free  of
all other  patient  specimens  [2]. Post-ampliﬁcation
and ultraviolet  (UV)  photography  should  be  per-
formed  in  specialized  rooms  with  a  UV  containment
area. The  use  of  UV  aprons  should  be  made
mandatory within  this  area.  The  equipment  used
within  UV  area  should  not  be  used  outside  of  the
area.
Laboratory equipment
In  resource-limited  settings,  there  is  lack  of
decentralized  molecular  diagnostic  testing  and
sparse access  to  centralized  medical  facilities.
Because many  molecular  technique  apparatuses
are expensive  to  install  in  average  microbiol-
ogy laboratories,  cost-effective  equipment  can  be
used. Portable  molecular  technologies  especially
designed for  developing  countries  are  available;
for example,  portable  nucleic  acid  thermocy-
clers are  battery  powered  and  cheaper  than
bench top  units.  These  portable  thermocyclers
can perform  PCR,  reverse  transcriptase-PCR  and
many formats  of  isothermal  ampliﬁcation,  includ-
ing nucleic  acid  sequencing-based  ampliﬁcation,
strand displacement  ampliﬁcation,  rolling  circle
ampliﬁcation,  loop-mediated  isothermal  ampliﬁca-
tion, and  helicase-dependent  ampliﬁcation.  There
are valuable  applications  of  these  portable  ther-
mocyclers  in  diagnostic  microbiology  and  biothreat
detection.  Various  infectious  agents  have  been
identiﬁed  using  these  portable  apparatuses,  such  as
HPV, N.  gonorrhoeae, C.  trachomatis, Treponema
pallidum and  T.  vaginalis  [33]. Several  varieties  of
portable apparatuses  are  commercially  available;
important evaluation  criteria  for  each  technology
include maturity,  power  requirements,  cost,  sen-
sitivity, speed,  and  manufacturability.  Ultimately,
the needs  of  a particular  market  will  lead  to  user
requirements  that  drive  the  decision  between  avail-
able technologies.
There is  a  serious  issue  with  instrument  mainte-
nance in  developing  countries  because  the  lack  of
functional  equipment  will  decrease  the  efﬁcacy  and
quality of  the  laboratory  procedures  [22].  For  qual-
ity assurance,  the  facility  should  have  documented
procedures for  the  maintenance,  calibration,  ver-
iﬁcation and  validation  of all  equipment.  Various
successful  infection  control  programs  have  come  to
a halt  in  a number  of  developing  countries  due  to
the lack  of  maintenance  and  service  of  the  labora-
tory equipment.  Equipment  failure  and  breakdown
delays laboratory  output;  thus,  equipment  main-
tenance  should  be  given  priority.  Selection  of
equivalent  brands  is  important  and  depends  on  the
service provided  by  the  local  dealer  [19]. Some-
times it  is wiser  to  buy  simple  instrumentation
that is  user  friendly  and  less  expensive  rather
than opting  for  automated  instruments.  Sophisti-
cated electric  equipment  must  also  be  avoided
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in  developing  countries  unless  it  is  essential  due
to the  irregular  supply  of  electricity  and  the  high
cost.
Furthermore,  the  laboratory  staff  should  receive
on-site training  for  equipment  by  the  manufacturer
[34].  Thermocyclers  are  important  instruments  for
molecular microbiology  laboratories;  any  change
in the  performance  of  thermocyclers  will  directly
affect the  precision  of  the  tests.  Determination
and documentation  of  cycling  time  or  any  errors
should be  recorded;  ﬂuctuations  in  the  cycling
times should  serve  as  warnings  and  be  adjusted.
Additionally, chiller,  heater  and  block  tempera-
ture adjustments  should  be  performed  according  to
the manufacturer’s  recommendations  [35].  Pipettes
and micro-pipettes  are  used  in  almost  every  step
of routine  procedures;  therefore,  special  atten-
tion should  be  paid  to  their  usage  because  they
are the  prime  source  of  errors.  Pipette  calibrations
should be  performed  regularly  using  recommended
guidelines. Special  care  should  be  given  to  the
PFGE  apparatus,  with  proper  cleaning  of  the
tank performed  before  and  after  every  run  and
the electrodes  changed  regularly.  Most  molecu-
lar instruments  are  expensive.  Recently,  a  reagent
rental agreement  program  has  been  introduced  as  a
means to  acquire  molecular  instruments;  however,
the availability  of  this  program  depends  upon  the
manufacturer  [36].
Laboratory practice
General  laboratory  practice  requires  careful  atten-
tion, including  regular  cleaning  and  strict  monitor-
ing of  all  methods  performed.  The  practice  code
is a  list  of  the  most  essential  procedures  used
in basic  good  microbiology  practices.  It  is  impor-
tant to  develop  written  laboratory  practices  and
methods  for  safe  laboratory  operations.  Interna-
tional biohazard  signs  must  be  displayed  on  the
laboratory  door  if  the  laboratory  is  working  with
isolates  from  risk  group  2 or  above.  Only  authorized
personnel should  be  given  access,  and  laboratory
doors should  always  be  closed.  All  of  the  surface
areas should  be  cleaned  before  and  after  usage.
Working stations,  tables,  refrigerators  and  reagent
containers  should  be  regularly  swabbed  with  70%
ethyl alcohol  [37].  The  use  of  disinfectants  recom-
mended  by  the  environmental  protection  agency
should  be  promoted.  Cleaning  should  be  performed
on all  surfaces,  benches,  racks,  tiles,  rockers  and
wherever  a  spill  occurs.  For  molecular  procedures
(especially PCR  and  PFGE),  each  working  area
should contain  dedicated  reagents,  materials  and
pipetting  devices.  Reagents  should  be  prepared  in
small aliquots  to  avoid  contamination  [3].
Laboratory personnel requirement
Increasing  the  number  of  well-trained  and  skilled
personnel is  a major  limitation  in  developing
countries. Although  there  is  a  steady  demand  for
appropriate  and  adequate  workers,  governmen-
tal policies  restrict  the  ﬂow  of  skills.  Laboratory
personnel should  be  trained  with  all  safety  meas-
ures. Updating  staff  about  the  control  measures
for laboratory  biohazards  is a  key  to  preventing
laboratory-acquired  infections.  An  effective  labo-
ratory program  should  be  introduced  by  integrating
safe laboratory  practices  into  the  basic  training
of the  personnel  [38]. Training  should  include  all
safety measures  for  handling  hazardous  materials,
such  as  aerosol  inhalation,  ingestion  of  specimens,
percutaneous exposure  to  sharp  instruments,  and
handling  and  disposal  of  hazardous  material.  The
skills required  for  molecular  techniques  are  more
precise  and  include  micro-pipetting,  DNA  handling
and disposal,  software  manipulation  during  analysis
of the  results  and  reporting  [26]. Personal  protec-
tive equipment  should  always  be  used  as  a  ﬁrst  line
of safety:
a) Protective  laboratory  coats  must  be  worn  at  all
times inside  the  laboratory.
b) Hand  protection  should  be  followed  by  wearing
disposable gloves  made  of  nitrile  or  chloroprene.
c) Eye  and  face  protection  should  be  made  com-
pulsory whenever  a splash  or  spill  occurs.
Waste management
In  most  low-income  regions  and  especially  in  Asian
countries  the  management  of  medical  waste  is  a
severe problem;  only  a  handful  of  centers  can
process medical  waste  efﬁciently.  Waste  gener-
ated by  microbiology  laboratories  in  the  form  of
specimen  samples,  culture  plates  and  tubes  all
carry a  high  potential  risk  of  infection  and  need
to be  managed  effectively.  Most  of  the  biomed-
ical waste  produced  should  be  decontaminated,
discarded  or  incinerated  [39].  Non-infectious  mate-
rials such  as  glassware  are  recyclable  and  can  be
sterilized.  Decontamination  should  be  performed
by steam  autoclaving.  Contaminated  sharp  wastes,
such as  hypodermic  needles,  disposable  knives,  and
syringes,  should  be  discarded  in  a puncture-proof
bag [32].
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Prospective instructions
Due  to  the  lack  of  ﬁnancial  resources  in  develop-
ing countries,  partnerships  between  public,  private
and commercial  sectors  should  be  maintained  in
order to  build  a  well-equipped  laboratory.  Fund-
ing bodies  should  address  the  ﬁnancial  inequity,
and an  appropriate  balance  should  be  encouraged
that emphasizes  laboratory  infrastructure  and  man-
agement.  There  should  be  a  focus  on  accurate
identiﬁcation  and  the  use  of  highly  reproducible
methods. The  funding  bodies  should  target  long-
term training  and  education  of  future  laboratory
personnel. There  should  be  improved  communica-
tion between  the  laboratory  and  clinicians,  which
could affect  the  accuracy  of  disease  treatment.
Policy makers  and  health  care  personnel  must
understand that  accurate  and  rapid  identiﬁcation
are important  for  the  prevention  and  treatment  of
disease. It  is  very  important  to  maintain  a well-
maintained clinical  microbiology  laboratory  using
current knowledge  to  control  infections.  Build-
ing a  molecular  microbiology  laboratory  facility  to
provide rapid,  accurate  and  reliable  tests  will  help
health care  staff  to  deliver  more  effective  treat-
ment regimens,  thereby  reducing  mortality,  overall
expenditure  of  health  care  resources  and  improv-
ing the  quality  of  health  care  services  in  developing
countries.
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Acinetobacter baumannii in developing countries
A Ulu-Kilic, SS Ahmed, E Alp, M Doğanay*
Challenge of intensive care unit-acquired infections and 
Abstract
Introduction
Nosocomial intensive care unit-acq-
uired infections and antimicrobial 
resistance are global problems, and 
many epidemiological studies are 
carried out, especially from develop-
ed countries. However, available da-
ta of patient population and charact-
eristics of intensive care units are v-
ery limited in developing countries. 
The prevalence of infection and mor-
tality rates are higher in countries 
with limited resources associated w-
ith the quality of care. Infection cont-
rol strategies such as hand hygiene, 
rational antibiotic utilisation, contin-
uous education and performance fe-
edback demonstrated a significant r-
eduction in the infection rates in th-
ese countries. Acinetobacter bauma-
nnii is common cause of nosocomial 
infections worldwide. In recent yea-
rs, interest in infections caused by A. 
baumannii has gradually increased, 
and current studies indicate that this 
pathogen is more resistant and viru-
lent, becoming a serious nosocomial 
threat. This critical review discusses 
the prevalence of A. baumannii and 
other intensive care unit acquired i-
nfections in developing countries.
Conclusion
Intensive care unit-acquired infecti-
ons caused by resistant organisms, 
prominently A. baumannii, are a glo-
bal challenge.  Large scale studies of 
intensive care unit-acquired infecti-
ons in developing countries and
Introduction
Patients in intensive care units (ICU-
s) are a significant subgroup of all h-
ospitalised patients, accounting for 
about 25% of all hospital infections. 
The prevalence of ICU-acquired infe-
ctions is significantly higher in deve-
loping countries than in industrialis-
ed countries, varying between 4.4% 
and 88.9%. Furthermore, device-ass-
ociated infection rates in developing 
countries, especially ventilator-asso-
ciated pneumonia (VAP) followed by 
central venous catheter-related blo-
odstream infections (CRBSIs), occur 
at a higher frequency than in Europ-
ean countries and USA1–3. The maj-
or problems associated with increas-
ed nosocomial infections in these co-
untries are low compliance of hand 
hygiene, excessive number of patien-
ts and work-load, inadequate staff a-
nd personal protective equipment, 
and late establishment of infection c-
ontrol programmes4. Increasing dru-
g resistance and the spreading of m-
ulti drug-resistant (MDR) pathogen-
s in the ICU environment, results in 
limited therapeutic options and pro-
longed hospitalisation. Consequentl-
y, ICU-acquired infections have been 
associated with significant morbidit-
y, mortality and rising healthcare co-
sts in developing countries with lim-
ited resources5.
Acinetobacter baumannii is a comm-
on cause of nosocomial infections w-
orldwide. In recent years, interest in 
infections caused by A. baumannii g-
radually has increased, and current 
studies indicate that the pathogen is 
more resistant and virulent, becomi-
ng a serious nosocomial threat6. The
aim of this critical review is to assess the problems associated with infecti-ons caught prevalent in ICUs in dev-eloping countries.
Discussion
The authors have referenced some 
of their own studies in this review. 
These referenced studies have been 
conducted in accordance with the D-
eclaration of Helsinki (1964) and the 
protocols of these studies have been 
approved by the relevant ethics co-
mmittees related to the institution in 
which they were performed. All hu-
man subjects, in these referenced st-
udies, gave informed consent to par-
ticipate in these studies.
Characteristics of ICUs and 
spreading of infection
ICUs are specialised departments of 
hospitals looking after critically ill p-
atients. Nosocomial infections affect 
about 30% of patients in ICUs. Incre-
ased risk of infection in the ICU pati-
ents is associated with severity of ill-
ness, underlying conditions, exposu-
re to multiple invasive devices and 
procedures (endotracheal intubatio-
n, urinary catheters, etc.) and increa-
sed patient contact with healthcare 
personnel. ICU staff and the equipm-
ent used for patient care during the 
hospitalisation are the primary sour-
ces of cross transmission of nosoco-
mial pathogens. Several invasive de-
vices have been used on ICU patients 
to treat or monitor their care; nosoc-
omial infections mostly VAP, CRBSI 
and catheter-associated urinary tra-
ct infections (CAUTI) are more com-
mon complications of care provided 
in ICU. The ICU mortality rate of inf-
ected patients was 25%, two times 
more than non-infected patients in 
an international study7.
*Corresponding author 
E-mail: mdoganay@erciyes.edu.tr
Department of Infectious Disease, Faculty of 
Medicine, Erciyes University,  38039-Kayseri/ 
Turkey
guidelines including globally applic-
able infection control strategies to 
reduce these infections are essential.
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Available data for patient popula-tion and characteristics of ICUs are lacking in developing countries. The prevalence of infection and mortal-
ity rates are higher in countries with limited resources associated with the 
quality of care8. Main problems in de-
veloping countries are understaffing, poor infrastructure in ICUs and over-crowding. Lack of injection and blood 
transfusion safety is still a problem in most African countries9. Risk factors 
of infections in critically ill patients are similar in all developed and devel-oping countries including age, comor-bid diseases, mechanical ventilation, duration of hospitalisation, length of 
ICU stay, immune  suppression and 
greater disease severity. Improve-ment of ICU service and training of the 
staff and accountability are needed to provide a solution in these countries.
Current situation and major reason 
of infections in ICUsWhile the nosocomial ICU infections and antimicrobial resistance are global problems, there have been 
many epidemiological studies carried 
out especially in western countries. Such studies have provided valuable information about the prevalence and 
epidemiology of infection in critically 
ill European patients. Additionally, these studies emphasised that adher-ence to infection control measures 
significantly reduced the prevalence of these infections7. VAP, CRBSI and CAUTI are the most important noso-comial infections in the ICUs world-wide. Lack of data collection and absence of policies and guidelines of infection control are the major prob-lems to estimate the burden of ICU infections and adherence to infection control measures in developing coun-tries. Therefore, International Noso-comial Infection Control Consortium (INICC) aimed to provide surveillance data and gives performance feedback to reduce the infection rates focusing 
on education, hand hygiene and other basic infection control measures in developing countries.
INICC is an international non-
profit, open, multicentre, collabora-tive healthcare-associated infection control program with a surveillance 
system based on that of the US Na-
tional Healthcare Safety Network. Several developing countries includ-
ing Argentina, Turkey, Colombia, 
India, Mexico, Brazil, and Peru have participated in INICC. The surveil-lance data from academic teaching, 
private community and public hospi-
tals get involved. By type of the ICUs, 
patients were mostly hospitalised in 
medical, surgical, coronary, paedi-atric and newborn units. According to the INICC data, device associated infection rates reported in ICUs in developing countries were 19.5 for VAP, 9.2 for CRBSI and 6.5 for CAUTI 
in 1000 device days. Compared with the National Nosocomial Infections Surveillance of USA, these rates were 
3.1, 2.3 and 1.5, respectively10.The results of INICC studies also concluded that infection control 
strategies significantly reduced in-fection rates in developing countries. After multidimensional approach in-terventions (education, bundles, per-formance feedback, etc.), implement-ed reduction rates from the reported baseline were 55.8 % in VAP, 54 % in CRBSI and 37% in CAUTI10–12.Available information about epi-
demiology and surveillance of ICU-acquired infections in most African countries are still lacking and un-
derestimated, reflecting the limited resources and serious economic problems of this continent. After the 
implementation of WHO’s hand hy-
giene improvement strategy, favour-able results were reported and dem-onstrated that these promotions are effective in low-income settings9.
Major infectious agents in ICUsThe European Prevalence of Infec-
tion in Intensive Care study has 
mostly included data from western European countries. The most com-mon site of infection was the respi-
ratory system (64%), followed by 
abdomen (20%), bloodstream (15%) 
and genitourinary system (14%). The causative agents of infections were 47%  gram- positive pathogens, 62% gram-negative pathogens and 19% fungal pathogens. Staphylococ-
cus aureus (20%) was the most com-mon gram-positive pathogens, while 
Pseudomonas species (20%) and 
Escherichia coli (16%) were the most common gram-negatives reported in patients7. This study also concluded that the infection rates were related to healthcare spending, with higher rates of infection reported in coun-tries that had a lower proportion of gross domestic product devoted to 
healthcare. More recently, another 
study from Turkey reported chang-ing prevalence and antibiotic sus-
ceptibility of pathogens in ICUs. A. 
baumannii (21.8%) was the most common gram-negative pathogen with an increasing carbapenem re-sistance. On the other hand, S. au-
reus is still the most prevalent gram- positive pathogen, but the incidence decreased from 18.6% to 4.8%. Methicillin resistance decreased in S. 
aureus from 96% to 54%13.
Antibiotic resistance problems  
in ICUsAntibiotic resistance rates among bacterial pathogens isolated in as-sociation with ICU infections rep-resent major problem worldwide. 
Especially, treatment becomes more challenging in gram-negative organ-isms causing serious infections in ICUs including pneumonia, blood-stream infections, wound or surgi-cal site infections, and meningitis. 
These organisms exhibit multidrug resistance, and therapeutic alterna-tives have declined due to stagna-tion in novel antimicrobial agents 14. An update of Infectious Diseases
Society of America in 2009 identi-
fied five gram-negative organisms as ‘ESKAPE’ including Pseudomonas 
aeruginosa, A. baumannii, Klebsiella 
pneumoniae, E. coli and Enterobacter species associated infections with 
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significant morbidity, mortality and 
financial costs15.Carbapenems are preferred anti-biotics for severe infections of ICU-
acquired infections caused by drug-resistant gram-negative bacteria 
especially for the extended spectrum beta-lactamase producers. Carbap-enem resistance among P. aerugi-
nosa and A. baumannii and recently 
Klebsiella species has emerged with increasing prevalence. These patho-gens cause serious ICU infections, and clinicians need to use old drug alternatives such as ‘colistin’ in the treatment of serious infections due to MDR gram-negative bacteria. Clin-
ical experience about colistin used in the treatment of Acinetobacter infec-
tions is mostly reported. Outcomes were favourable with a success rate of 83.8% and side effects (renal fail-
ure, seizures, etc.) reported with a rate of 4.6%16.Since A. baumannii is the most prevalent gram-negative pathogen, with increasing carbapenem resis-
tance, tigecycline is a new option for the treatment of infections caused 
by this organism. Positive outcomes were reported 81% of patients, simi-lar to colistin rates. Authors also reported better outcomes with this agent in the treatment of surgical site infections than VAP or bacteremia17.A novel acquired carbapenemase (class B), New Delhi Metalo-beta-lactamase-1 (NDM-1), which can be 
produced by Enterobactericeae spe-
cies, was first identified and report-ed from Sweden in 2009 originating from India. Later, NDM-1 was detect-ed in isolates obtained from patients 
in India and Pakistan, followed by 
the Middle East and Egypt, and later from several different countries from all continents. This pathogen is rap-
idly spreading worldwide, causing a global public health threat. Colistin 
and tigecycline seems to be effective 
in vitro against these isolates18.Methicillin-resistant S. aureus 
(MRSA) and vancomycin-resistant enteroccocus represent the most 
commonly reported gram-positive MDR pathogens in the ICU. MRSA 
causes community- and healthcare associated infections, and about 
20% of the healthy subjects persis-
tently have nasal colonisation with 
S. aureus. According to the European Antimicrobial Resistance Surveil-
lance System (EARSS) reports19, MRSA prevalence decreased from 41.9% in 2006 to 22.4% in 2012. Studies re-ported that decreased antibiotic con-sumption strategies (cephalosporins, quinolones) were associated with the decline of prevalence of MRSA19. Also, emergence and spread of resis-tant gram-negative pathogens seem 
to occur as global endemicity, causing 
a change in the epidemiology world-wide. During the last decade, vanco-
mycin-intermediate S. aureus strains were reported in America as a result 
of long term and excessive use of van-
comycin in hospitals. However, this 
do not currently seem to be a serious 
problem in Turkey, since a multicentre 
study determined no resistance or de-
creased susceptibility to vancomycin20.
Annual proportion of vancomycin resistance among Enterococcus fae-
cium in 2012 was reported to be the highest at 45% compared to previous 
years according to EARSS19.Emergence of resistant pathogens generates a global wave spreading 
between continents. Consequently, antibiotic resistance is a worldwide problem requiring co-ordinated in-ternational surveillance and infection control measures.
Acinetobecter infections, molecular 
epidemiology and drug resistance 
problem in ICUs
A. baumanni is an aerobic, non-fermentative gram-negative cocco-bacillus. Acinetobacter species have 
low virulence; however, they are opportunistic agents in hospitalised 
and critically ill patients, causing 
VAP, bacteraemia and urinary tract infections. The bacterium is strongly associated with environmental con-tamination. The pathogen is adapted 
to survive and colonise in the hospi-
tal environment, especially in ICUs, and is responsible for serious out-breaks20. Nosocomial pneumonia is the most common pathogens clinical presentation. A. baumannii is among the most common to cause late-on-set VAP and the second most com-mon pathogen to cause bloodstream infections acquired in hospitals15,21. Further, A. baumannii is responsible for various nosocomial infections in-
cluding central nervous system, skin and soft tissue and bone infections22.MDR Acinetobacter isolate increase 
therapeutic difficulty and result in 
high mortality rates. A. baumannii has become resistant to almost all antimicrobial agents including ceph-
alosporins, quinolones, aminoglyco-
sides and broad spectrum β-lactams including carbapenems. Although 
carbapenems have been successfully used in treating most gram-negative nosocomial infections, emergence of MDR pathogens such as A. baumannii has menaced the use of this substan-tial class of drugs. Several studies have shown increased ‘carbapenem resistance’ throughout the world15–17.Wide range of resistance mecha-nisms are involved, such as (i) loss of outer membrane proteins (porin channels) causing decreased perme-
ability to antibiotics, (ii) alterations in penicillin-binding proteins, (iii) over-
expression of efflux pump proteins, further decreasing concentration of 
antibiotics within the cell and (iv) hy-
drolysis of β-lactams by β-lactamases 
encoded by either plasmids or chro-mosome23. Furthermore, combina-tion of these mechanisms can cause high levels of resistance to carbapen-ems in Acinetobacter species. Carbap-enem-resistant A. baumannii is asso-ciated with prolonged hospitalisation 
and a higher mortality rate.
Many β-lactamases have been characterised in A. baumannii; chro-
mosomally-encoded (AmpC type) cephalosporinases are common and inactivate all cephalosporins. Class-
A extended spectrum β-lactamases 
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(ESBLs) conferring resistance against penicillins and cephalosporins have also been described, such as VEB-1 from Argentina and Belgium; PER-
2 from Bolivia, Turkey, Romania, Argentina and Korea; SHV-12 from China, and CTX-M-2 and CTX-M-3 from Japan and Bolivia23–25. Metallo-
β-lactamases (MBLs) belonging to 
class-B ESBLs are able to hydrolyse 
all β-lactams except aztreonam. MBLs such as IMP-1 are isolated from Japan, 
Korea and other Pacific regions, and 
VIM- and SPM-types are widespread in Korea and Latin America26. Class D 
OXA β-lactamases are strong penicil-
linases, able to hydrolyse extended spectrum cephalosporins and inacti-vate carbapenems. Plasmid-mediated OXA-58 is isolated from Iraq, Argen-
tina, Greece, Turkey, Romania, Kuwait and western Europe27–29. Moreover, 
OXA-51 is chromosomally mediated 
and naturally present in A. bauman-
nii. Other OXA-β-lactamases include OXA-23-like, OXA-24, OXA-25, OXA-26, OXA-27 and OXA-40, which are 
able to hydrolyse carbapenems26.Since carbapenem resistance has been reported world wide newer alternatives such as colistin, sulbac-
tam, rifampicin and tigecycline and combinations of these antibiotics 
have arisen. Unfortunately, extensive 
use of colistin and tigecycline has resulted in resistance to these an-
tibiotics; this has been increasingly reported. Development of resistance 
to colistin and tigecycline is the most serious problem in gram-negative infections including Acinetobacter in ICUs. This is because infections with a bacterium resistant to all FDA- ap-proved antibiotics are in an incurable condition. Thereupon, these out-
comes clearly reveal the importance of understanding the mechanisms of drug resistance in these bacteria.Different combinations of colistin, 
carbapenems, sulbactam, aminogly-cosides and rifampicin were studied 
to find a solution to the therapeutic limitation of MDR and pandrug-re-sistant Acinetobacter strains. In vitro 
synergy of colistin and rifampicin combination seems promising, re-
quiring experience in clinical use30. Combination therapies are new thera-peutic options to decrease resistance rates and advised for preventing emergence of colistin resistance dur-
ing monotherapy. Optimum therapeu-tic alternatives for resistant Acineto-
bacter infections should be studied 
and clinical experiences with differ-ent combinations should be reported in future researches. 
Infection control in ICUs is rationale
Although it is difficult to solve some 
problems associated with financial hardship in developing countries, most solutions are simple and not 
resource demanding. Hand hygiene is the most important component reducing the spread of infections in ICUs. In countries with limited re-sources, structured training in hand 
hygiene and hand hygiene promotion campaigns have been reported to im-prove the adherence among health-care workers. Initial empirical thera-
py with broad-spectrum antibiotics is 
a life-saving strategy, which improves clinical outcome and minimise selec-tion of resistant organisms. It is also recommended to de-escalate these an-tibiotics according to culture and anti-
biotic susceptibility results. Antibiotic 
cycling is also an effective approach to control antibiotic resistance. Strict antibiotic policies in ICUs prevent the 
use of long term, unnecessary anti-biotics and shorten the duration of 
the antimicrobial therapy4. Conduct-ing infection surveillance and control activities in ICUs and rational antibi-otic utilisation policies are valuable measures for infection control. These measures provide current knowledge about antibiotic resistance patterns, 
early recognition and management of outbreaks, which is essential for infec-tion control31. Several healthcare set-tings have succeeded in reducing the 
risk by implementing with these sim-ple, low-cost interventions. Health-care facilities should provide periodi-
cal educational programmes to ICU staff for infection control and evaluate for effectiveness. Surveillance activi-
ties, hand hygiene promotions, ratio-nal use of antibiotics and other isola-
tion procedures need to be regularly 
supported and encouraged by good role models in institutions, local and governmental managers and other infection control organisations these 
should be extensively encouraged in developing countries31.Risk factors of Acinetobacter in-
fection are already known and acute 
vaccination and antibody-based im-mune therapies for patients at the risk of these infections looks promis-ing to prevent infections and improve outcomes.
ConclusionICU-acquired infections and antibi-otic resistance is a growing threat worldwide. Large scale studies of ICU-acquired infections in devel-oping countries are needed for un-derstanding the magnitude of the problem. Furthermore, guidelines 
including globally applicable infec-tion control strategies that constitute an effective solution to reduce these infections are essential.
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Abstract Epidemic clones of Acinetobacter baumannii,
described as European clones I, II, and III, are associated
with hospital epidemics throughout the world. We aimed to
determine the molecular characteristics and genetic diver-
sity between European clones I, II, and III from Turkey and
Azerbaijan. In this study, a total of 112 bloodstream iso-
lates of carbapenem-resistant Acinetobacter spp. were col-
lected from 11 hospitals across Turkey and Azerbaijan.
The identification of Acinetobacter spp. using convention-
al and sensitivity tests was performed by standard criteria.
Multiplex polymerase chain reaction (PCR) was used to
detect OXA carbapenemase-encoding genes (blaOXA-23-
like, blaOXA-24-like, blaOXA-51-like, and blaOXA-58-like).
Pulsed-field gel electrophoresis (PFGE) typing was used
to investigate genetic diversity. The blaOXA-51-like gene
was present in all 112 isolates, 75 (67 %) carried blaOXA-
23-like, 7 (6.2 %) carried blaOXA-58-like genes, and 5 (4.5 %)
carried blaOXA-24-like genes. With a 90 % similarity cut-off
value, 15 clones and eight unique isolates were identified.
The largest clone was cluster D, with six subtypes. Isolates
from clusters D and I were widely spread in seven different
geographical regions throughout Turkey. However, F clus-
ter was found in the northern and eastern regions of
Turkey. EU clone I was grouped within J cluster with three
isolates found in Antalya, Istanbul, and Erzurum. EU clone
II was grouped in the U cluster with 15 isolates and found
in Kayseri and Diyarbakır. The blaOXA-24-like gene in
carbapenemases was identified rarely in Turkey and has
been reported for the first time from Azerbaijan.
Furthermore, this is the first multicenter study in Turkey
and Azerbaijan to identify several major clusters belonging
to European clones I and II of A. baumannii.
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Introduction
Acinetobacter baumannii is a Gram-negative pathogen often
associated with nosocomial infections, including ventilator-
associated pneumonia, meningitis, central line-associated
bloodstream infections, and urinary tract infections. Listed by
the Infectious Diseases Society of America (IDSA) as one of the
six top-priority dangerous microorganisms [1], it has also been
recognized as a worldwide emerging cause of healthcare-
associated outbreaks. The pathogen is well adapted to the hos-
pital environment and capable of continuously spreading to oth-
er patients. In recent years, multidrug-resistant A. baumannii
have been increasingly reported worldwide. Themost important
concern is their multidrug resistance to almost all available an-
tibiotics, such asβ-lactams, fluoroquinolones, tetracyclines, and
aminoglycosides, resulting in prolonged duration of hospitaliza-
tion and high mortality rates. Carbapenems such as imipenem
and meropenem have been used to treat multidrug-resistant
A. baumannii infections; however, carbapenem resistance in
A. baumannii has raised great concern worldwide [2].
The majority of A. baumannii epidemics are caused by a
limited number of strains, known as “European clones” or
“International clones”. Epidemic clones of A. baumannii, de-
scribed as European clones I and II, are widely spread across
Europe and found to cause severe hospital outbreaks. Recently,
a third pan-European outbreak clone (clone III) was described.
These three clones are thought to cause huge epidemics not only
in Europe, but also other parts of the world [3]. Carbapenem
resistance in A. baumannii is attributed to the oxacillinase
(OXA) group. OXAs with the ability to hydrolyze carbapenems
appear to be mostly associated with A. baumannii and have
been reported worldwide, including in Turkey and regional
areas like Iran, Greece, and Georgia [4]. Changes in the preva-
lence of carbapenem resistance genes of the OXA type in
A. baumannii circulating among local geographical areas have
recently been documented [5]. At present, little is known about
the dissemination of European clones and carbapenem-resistant
A. baumannii isolates across Turkey and Azerbaijan.
This multicenter study was carried out with the aims of: (i)
establishing a clonal relationship with European clones I, II,
and III, and (ii) assessing the prevalence of carbapenem resis-
tance genes in the investigated isolates. The results obtained
will be helpful in determining the local expansion of some
special clones or dissemination of international clonal lineages.
Materials and methods
Bacterial isolates
In this observational study, a total number of 112 bloodstream
isolates of multidrug-resistant Acinetobacter spp. were collect-
ed from 11 hospitals across Turkey andAzerbaijan in the period
2014–2015. Isolates from Azerbaijan were collected from one
hospital in Baku. All the isolates were tested for antimicrobial
susceptibility in their respective hospitals and found to be mul-
tidrug-resistant. Three standard representatives of the endemic
pan-European clonal lineages I, II, and III were included in this
study. Isolates were collected by standard methods, isolated in
pure culture on Luria–Bertani agar plates, and identified with
the Vitek 2 system (bioMérieux, Marcy-l'Etoile, France).
Bacterial growth and DNA extraction
All Acinetobacter isolates were grown in Luria–Bertani broth
(Difco Laboratories, Detroit, MI, USA) at 37 °C for 24 h with
shaking. Genomic DNA was extracted using the PureLink
Genomic DNA kit (Invitrogen, Carlsbad, CA, USA).
Bacterial identification
Identification at the species level was centrally reconfirmed
with the API 20 NE system (bioMérieux, Marcy-l'Etoile,
France). Polymerase chain reaction (PCR) was performed
for the blaOXA-51-like gene with primers 5′-TAATGCTTTGA
TCGGCCTTG-3′ and 5′-TGGATTGCACTTCATCTTGG-3′.
The PCR conditions were initial denaturation at 94 °C for 5min,
30 cycles of 94 °C for 25 s, 52 °C for 40 s, and 72 °C for 50 s,
and a final elongation at 72 °C for 6 min.
Multiplex PCR and DNA sequencing for OXA genes
A multiplex PCR assay was used to detect OXA
carbapenemase-encoding genes (blaOXA-23-like, blaOXA-24-like,
and blaOXA-58-like). The amplification conditions were initial
denaturation at 94 °C for 5 min, 30 cycles of 94 °C for 25 s,
52 °C for 40 s, and 72 °C for 50 s, and a final elongation at
72 °C for 6 min. The entire blaOXA-23-like, blaOXA-24-like, and
blaOXA-58-like coding regions were amplified and sequenced
using primer pairs as previously described [6].
Molecular typing by PFGE
Purified DNA from all isolates was prepared in agarose blocks
and digested with 30U SmaI (New England Biolabs, Ipswich,
MA, UK). Agarose gel electrophoresis was performed in 1 %
gels (Bio-Rad, Hercules, CA, USA) in 0.5X TBE buffer in an
orthogonal-field alternating pulsed-field gel electrophoresis
(PFGE) (CHEF-DR III) (Bio-Rad, Hercules, CA, USA) for
20 h at 12 °C. The run conditions were 200 V with a pulse
angle of 120° and pulse times of three phases as follows: 20s
for 8 h, 10s for 8 h, and 5 s for 4 h. A Lambda PFGE ladder
(Bio-Rad, Hercules, CA, USA) was used to provide molecular
size markers, and the gels were stained with GelRed (0.5mg/L)
(Biotium, Hayward, CA, USA). Restricted DNA bands were
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visualized using a GE Healthcare imager (ImageQuant 100,
Uppsala, Sweden).
Results
Bacterial identification
The biochemical test with the API 20NE system (bioMérieux,
Marcy-l'Etoile, France) identified Acinetobacter species.
Furthermore, the blaOXA-51-like gene was present in all 112
isolates, confirming that all isolates are A. baumannii.
PCR and DNA sequencing for OXA genes
PCR assays for the detection of different β-lactamase genes
were performed with all isolates. The blaOXA-23-like gene was
the most prevalent, being detected in 75 (67 %) of the isolates.
The entire blaOXA-23-like gene sequence was determined in 75
isolates, which confirmed the presence of the blaOXA-23-like
gene. This gene was found in every region of Turkey and
Azerbaijan. Five (4.5 %) isolates carried the blaOXA-24-like
gene and were found in the northern and eastern parts of
Turkey, including Azerbaijan, and 7 (6.2 %) carried the
blaOXA-58-like gene spread across Turkey (Fig. 1).
Molecular typing
At a similarity cut-off value of 90%, 15 clones and eight unique
isolates were identified, as shown in Fig. 2. The largest was
cluster D with six subtypes. Isolates from clusters D and I were
widely spread in seven different geographical regions through-
out Turkey. However, cluster F was found in the northern and
eastern regions, such as Trabzon, Samsun, Erzurum, and
Azerbaijan. The blaOXA-23-like gene was detected in almost all
the clusters spread across all the regions from Turkey and
Azerbaijan. The blaOXA-24-like gene was detected in clusters
B, D, F, and M only in Turkey. The blaOXA-58-like gene was
detected in clusters B, F, I, and U. EU clone I was grouped
within cluster J with three isolates (Fig. 2). EU clone II was
grouped in cluster U with 15 isolates and found only in Kayseri
and Diyarbakır. No similarity was found for EU clone III.
Discussion
Recent reports of hospital outbreaks have documented the
spread of carbapenem-resistant Acinetobacter species from
Europe, the Middle East, Turkey, and Eurasia [7]. Early rec-
ognition of the presence of these resistant Acinetobacter spp.
clones is necessary in order to prevent their spread within the
Fig. 1 Geographical distribution of the most common clones with their resistance genes from 11 centers across Turkey and Azerbaijan
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hospital environment.Multidrug-resistant strains often spread,
causing outbreaks throughout entire cities, countries, and con-
tinents, especially lineages of European clones. Clonal out-
breaks due to A. baumannii strains producing OXA-23
carbapenemase have been reported in Brazil [8] and, more
recently, in Korea [9] and France [10].
Many studies [8, 10–12] on A. baumannii nosocomial in-
fection reported the co-existence of OXA-23 together with
OXA-51 in most isolates of this species, corresponding with
this study, in which OXA-23 was the most prevalent
carbapenemase among all carbapenem-resistant isolates. The
results of this study supported the proposal that blaOXA-51-like
genes are detected in A. baumannii and Acinetobacter
nosocomialis strains. The blaOXA-24-like gene was first identi-
fied in Izmir in the far western region of Turkey in 2013 [13].
In this study, the rarely identified blaOXA-24-like gene in Turkey
and for the first time from Azerbaijan has been reported.
Interestingly, in this study, this gene was identified again from
Izmir and Erzurum, in the eastern region of Turkey. OXA-24
carbapenemase involved in moderate level carbapenem resis-
tance can moderately hydrolyze imipenem and meropenem.
OXA-24 was reported from Erzurum (eastern Turkey), Izmir
(western Turkey), and Azerbaijan (present in three isolates).
Two isolates were reported to have OXA-24 belonging to the
F clone, which is the most common clone in Azerbaijan. One
isolate reported OXA-24 belonging to the B clone, the most
common clone in Izmir.
There has been an increase in the occurrence of blaOXA-58-
like genes nowadays throughout Turkey, since earlier studies
reported less prevalence; in this study, we observed that 6.2 %
of isolates carried blaOXA-58-like genes. First, OXA-58 was
reported from France in 2003 [14], then in Turkey with plas-
mids bearing blaOXA-58-like spread among multiple clones of
A. baumannii. A recent study reported blaOXA-58-like in three
continents over a period of 10 years [15]. In contrast, the
results of this study showed that blaOXA-58-like was more prev-
alent in eastern Turkey, such as Trabzon, Erzurum, and
Diyarbakır and less prevalent in western Turkey, being
Fig. 2 Pulsed-field gel electrophoresis (PFGE) profiles and dendrogram showing 112 isolates and three EU clones of Acinetobacter baumannii digested
by SmaI enzymes with a cut-off value of 90 %
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reported only in Izmir. Due to this plasmidic location, the
distribution of this gene should be monitored. Furthermore,
an earlier study conducted by Metan et al. [16] in 2013 in one
of the collaborative centers in Kayseri reported a high preva-
lence of blaOXA-58-like, unlike the current study, in which 60%
of isolates carried blaOXA-23-like genes, resulting in a change in
the epidemiology of OXA genes. There are no earlier studies
performed on OXA genes in other collaborative centers in-
cluded in this study. However, in another study in 2010 [17],
from a hospital in Zonguldak, northeastern region of Turkey, a
high prevalence of blaOXA-58-like was reported. Although this
hospital was not one of the collaborative centers in this current
study, regions close to Zonguldak like Istanbul and Samsun
showed a high prevalence of blaOXA-23-like genes.
A high degree of genetic similarity was observed among all
the isolates, and 15 clones and eight unique isolates were iden-
tified. Clusters D and I were reported from seven geographical
regions, which means that isolates belonging to this cluster
have a wide presence in Turkey. Furthermore, isolates belong-
ing to cluster F were reported from multiple cities of geograph-
ically close regions, such as Trabzon, Samsun, Erzurum, and
Azerbaijan, which are in the northeastern parts of Turkey. To
the best of our knowledge, this is the first multicenter study in
Turkey and Azerbaijan to identify several major clusters be-
longing to European clones I and II of A. baumannii.
European clone I was found in Antalya, Istanbul, and
Erzurum, which are tourist destinations in Turkey. There could
be speculation that these clones could have disseminated by
tourists and travelers from Europe. Interestingly, EU clone II
was grouped in cluster U and found only in Kayseri and
Diyarbakır; however, these two regions are geographically far
from each other. In this present study, 16 % of all isolates
belonged to European clones I and II, suggesting their potential
to be particularly successful in Turkey. Further investigation of
European clones is required involving more samples and col-
laborative centers across Turkey and neighboring countries.
The current situation of immigration is a huge problem in
Europe, e.g., refugees from Syria heading towards Europe
through Turkey. There are a number of studies [18–20] on
multidrug resistance genes and other infectious agents carried
by Syrian and Iraqi refugees in Turkey and Europe. There are
possibilities of dissemination of epidemic clones from Turkey
to Europe, since Kayseri and Diyarbakır are geographically
very close to Syria and hosting thousands of refugees. There
could be possibility of dissemination of European clone II to
other parts of Turkey and Europe by immigrants and refugees.
Traveling and population dynamics have caused intensified
spreading of communicable diseases.Many infections have been
diagnosed during and after travel and migration, along with the
fact that there is a large number of Turkish communities living
across Europe who could carry these infectious clones while
visiting Turkey [21]. More observational studies are required in
order to investigate European and other epidemic clones with
hospitals across bordering cities and areas closer to Syria and
Iraq. This is a global problem and observational studies could
lower the burden on hospitals in Turkey and across Europe.
In conclusion, PFGE was more useful for local outbreak
investigations and was convenient for establishing relatedness
with clones that have spread globally. Carbapenem resistance
diffusion is attributable to rarely occurring blaOXA-24-like
genes. It is also interesting to speculate change in the epide-
miology of OXA genes from blaOXA-58-like to blaOXA-23-like;
however, this speculation could be strengthened by
performing further studies on OXA genes from the same and
other centers across Turkey and neighboring countries.
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nation of imipenem with sulbactam decreased the bacterial 
load in lung and liver. However, the addition of sulbactam to 
colistin and tigecycline had no significant effect on bacterial 
counts. Only the addition of sulbactam to imipenem showed 
better bactericidal activity compared to imipenem alone. 
 Conclusions: These results suggested that combining sul-
bactam with tigeycline or colistin does not increase the effi-
ciency of these antibiotics.  © 2014 S. Karger AG, Basel 
 Introduction 
 Acinetobacte r  baumannii is an important cause of nos-
ocomial infections. It can lead to serious infections in 
many organs and systems; sepsis is one of the most seri-
ous infections caused by this organism  [1–3] . Increasing 
levels of drug resistance in  A. baumannii have caused a 
serious therapeutic challenge. Although carbapenems 
were once considered the major treatment option, nowa-
days there has been a worldwide increase in infections 
 Key Words 
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Experimental sepsis · Sulbactam · Tigecycline · Colistin · 
Imipenem 
 Abstract 
 Background: In recent years, multidrug-resistant  Acineto-
bacter baumannii has been reported as an important nosoco-
mial pathogen, and treatment options are limited. The aim of 
this study was to investigate the additional effect of sulbac-
tam on monotherapy with colistin, tigecycline and imipenem 
in experimental sepsis with carbapenem-resistant  A. bau-
mannii in mice.  Methods: Sepsis was developed in 8- to 
10-week-old BALB/c mice by an intraperitoneal injection of 
 A. baumannii. Antibiotic was given intraperitoneally 2 h after 
bacterial inoculation. Each experimental group had 15 mice 
and was divided into 3 subgroups. Mice were sacrificed at 24, 
48 or 72 h. Lung, liver, heart and spleen samples were cul-
tured, and homogenates of lung and liver were used to de-
tect the number of colony-forming units per gram. Bacterial 
clearance was compared in lung and liver at different time 
points.  Results: Imipenem did not decrease the bacterial 
load, but the other antibiotics showed significant bactericid-
al activity compared with the control group, and the combi-
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caused by carbapenem-resistant Acinetobacter.  This pos-
es a serious challenge in the therapy alternatives for these 
cases  [4–6] . Colistin, tigecycline and sulbactam are com-
monly used antibiotics for the treatment of serious infec-
tions. However, the optimal therapeutic regimen is un-
certain and needs to be clarified  [7–9] .
 The aim of this study was to assess the efficacy of sul-
bactam alone and in combination with imipenem, colis-
tin and tigecycline against carbapenem-resistant  A. bau-
mannii in experimental sepsis.
 Materials and Methods 
 This study was carried out at the Hakan Cetinsaya Experimen-
tal and Clinical Research Center of Erciyes University. It was ap-
proved by the Local Ethical Committee for Animal Studies of Er-
ciyes University (No. 11/64).
 Laboratory Animals 
 BALB/c mice, aged 8–10 weeks and weighing between 20 and 
25 g, were used in this study. Mice were obtained from the Hakan 
Cetinsaya Experimental and Clinical Research Center, Erciyes 
University, Kayseri, Turkey. The mice were housed in separate 
cages and given ad libitum access to food and water. Animals were 
acclimatized in a 12-hour light/dark cycle. 
 Bacterial Isolate 
 A carbapenem-resistant (OXA-51-, OXA-58- and PER-1-pos-
itive)  A. baumannii  strain that was isolated from a patient with 
nosocomial sepsis was used. This strain was supplied by the De-
partment of Microbiology, Faculty of Medicine, Istanbul Univer-
sity. This isolate was stored at –80   °   C, and fresh subcultures were 
prepared prior to use. 
 Antimicrobials 
 Sulbactam (Mustafa Nevzat Pharmaceutical, Turkey), colisti-
methate sodium (Koçak Farma, Turkey), tigecycline (Wyeth, UK) 
and imipenem-cilastatin (MSD, Turkey) were used in the study. 
 Determination of Minimum Inhibitory Concentration Values 
 Minimum inhibitory concentration (MIC) values of sulbac-
tam, colistin, imipenem-cilastatin and tigecycline were deter-
mined by Etest (Diagnostic Liofilchem, Italy) according to the 
manufacturer’s guidelines and by the standard microdilution 
method  [10] . For Etests,  A. baumannii  suspension prepared to 0.5 
McFarland standard was cultured in Mueller-Hinton agar (Lab M 
Ltd., UK), and Etest strips were placed in the agar. After 24 h of 
incubation, the MIC values were determined. In a broth microdi-
lution test, the concentrations of all antibiotics used in this study 
were between 0.125 and 256 μg/ml.  Escherichia coli  ATCC 25922 
was used as a control. This test was performed according to the 
Clinical and Laboratory Standards Institute M07-A9 guidelines 
 [10] . MIC breakpoints for  A. baumannii against tigecycline, colis-
tin, sulbactam and imipenem-cilastatin were from the Clinical and 
Laboratory Standards Institute M07-A9 guidelines  [10] and 
 European Committee on Antimicrobial Susceptibility Testing 
breakpoint tables, version 3.1  [11] .
 Study Design and Experimentation 
 The mice were weighed and divided into 2 main groups, name-
ly controls (positive, negative) and the study group. A total of 135 
mice were used in this experiment. All experimental groups con-
sisted of 15 mice, and each group was divided into 3 subgroups of 
5 mice each. The study subgroups received the following treat-
ments: imipenem, colistin, tigecycline, sulbactam, imipenem + 
sulbactam, colistin + sulbactam or tigecycline + sulbactam. Sepsis 
was developed by the intraperitoneal injection of 10 8 colony-form-
ing units (CFU)/ml  A. baumannii suspension (determined in a 
preliminary study). All groups except the negative control group 
were injected with 0.5 ml of 10 8 CFU/ml  A. baumannii suspension. 
Two hours after intraperitoneal injection of the bacterial suspen-
sion, antibiotic treatments were initiated. Sulbactam (240 mg/kg), 
colistimethate sodium (5 mg/kg) and tigecycline (20 mg/kg) were 
given in 2 divided doses, and imipenem-cilastatin (200 mg/kg) was 
administered in 3 divided doses, all intraperitoneally. Drug dos-
ages were administered according to previous experimental stud-
ies  [2, 3] . All mice in the subgroups were sacrificed at 24, 48 or 72 h 
with an overdose of anesthetic (150 mg/kg ketamine hydrochlo-
ride, Pfizer, Turkey). Samples were taken from the lung, liver, 
spleen and heart and cultured on trypticase soy agar (Merck, 
 Germany) to check both for the growth of bacteria and develop-
ment of sepsis. A quantitative culture on trypticase soy agar was 
made from 10-fold dilutions of lung and liver homogenates. The 
bacterial load was detected as CFU per gram at 24, 48 and 72 h. 
 Statistical Analysis 
 Results were analyzed using SPSS 15.0 (SPSS Inc., Chicago, Ill., 
USA). Data were presented as the mean ± standard error of the 
mean. Logarithmic transformations were used when constructing 
statistical models to describe the relationship between two mea-
surements. One-way analysis of variance was used for data with a 
normal distribution pattern. All pairwise multiple comparison 
procedures were performed by the Student-Newman-Keuls meth-
od. A p value of <0.05 was considered significant.
 Results 
 Determination of MIC Values 
 The MICs were determined as 1 μg/ml for colistin, 
1 μg/ml for tigecycline, 16 μg/ml for sulbactam and >256 
μg/ml for imipenem-cilastatin. OXA-51, OXA-58 and 
PER-1 were positive in  A. baumannii. 
 Therapeutic Efficacy of Antibiotics 
 Lung and liver bacterial counts for treated and control 
animals are shown in  table 1 . The bacterial counts of lung 
and liver were not statistically significant between the 
control and imipenem group (p  > 0.05). However, the 
other antibiotics showed significant bactericidal activity 
in reducing lung and liver bacterial counts compared with 
the control group (p < 0.05). On the other hand, the ad-
dition of sulbactam to colistin and tigecycline had no sig-
nificant effect on bacterial counts in lung and liver. Only 
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the addition of sulbactam to imipenem showed better 
bactericidal activity compared with imipenem alone. 
When sulbactam was added to colistin, the bacterial load 
of lung was significantly higher at 72 h compared to co-
listin or sulbactam alone (p < 0.05). Colistin and tigecy-
cline monotherapy had earlier bactericidal activity com-
pared to sulbactam; however, at 72 h colistin and sulbac-
tam were the most active agents. Overall, the most effective 
therapy among all the groups was colistin.
 Discussion 
 A. baumannii  is the most important nosocomial 
pathogen worldwide, often affecting intensive care unit 
patients. The emergence of resistance to almost all anti-
biotics presents a serious problem in the clinical setting. 
Carbapenems have been considered the most active agent 
against multidrug-resistant pathogens. However, car-
bapenem-resistant isolates have been increasing world-
wide  [2, 12–15] . In recent years, carbapenem resistance 
rates were reported to be over 50%  [16–21] , and in our 
last study it was found to be 92% in intensive care units 
 [18] . Carbapenem-resistant  A. baumannii  poses a signif-
icant threat in hospitals, as therapeutic options are lim-
ited. Colistin, which was abandoned in the 1980s, was re-
introduced for clinical use after the emergence of car-
bapenem resistance. However, the clinical effectiveness of 
colistin is questionable and is reported to be as low as 20% 
 [22–24] . Resistance to colistin is the potential problem 
with colistin monotherapy. In recent years, many studies 
have investigated other antibiotics either as a monother-
apy or in combination with other antibiotics to increase 
the clinical success and to prevent resistance to colistin  [1, 
2, 19, 25–30] . Tigecycline and sulbactam have in vitro ac-
tivity against carbapenem-resistant  A. baumannii, and in 
some clinical studies the results were encouraging  [8, 13, 
30–32] . However, there is still debate about using these 
antibiotics as monotherapy or combination therapy in se-
rious  A. baumannii infections.
 Sulbactam is the most active β-lactamase inhibitor 
against  A.baumannii. In recent clinical studies, especially 
with high-dose sulbactam, it has shown a similar effec-
tiveness to imipenem and colistin in carbapenem-resis-
tant  A. baumannii infections. However, its single use is 
still controversial in life-threatening infections, and the 
development of resistance is a serious concern with 
monotherapy  [1, 4, 8, 23, 27] . In vitro studies have shown 
synergistic activity of sulbactam when combined with co-
listin, tigecycline and carbapenems  [1, 3, 6, 28, 31–33] . 
However, there still are not enough data about their in 
vivo efficacy, especially in serious infections. In this study, 
the therapeutic efficacy of sulbactam as monotherapy and 
in combination with colistin, tigecycline and imipenem 
in a sepsis model with carbapenem-resistant  A. bauman-
nii in mice was investigated. Sulbactam had no addition-
al bactericidal effect on colistin and tigecycline mono-
therapy, but when it was combined with imipenem it 
showed better bactericidal activity compared with imipe-
nem alone. However, imipenem + sulbactam did not have 
better bactericidal activity than sulbactam alone; the bac-
tericidal effect was probably due to sulbactam. In a previ-
ous experimental study, Montero et al.  [1] showed that 
colistin was not a good therapeutic option for treatment 
Table 1.  Effects of antibiotic therapies on bacterial counts in lung and liver tissues
Group  Bacterial count, log10 CFU/g
lung liver
24 h 48 h 72 h 24 h 48 h 72 h
Control (n = 15) 7.14±0.29a 6.63±0.17a 4.90±0.31a 7.11±0.23a 6.16±0.89a 4.88±0.31a
Sulbactam (n = 15) 5.23±0.69a, b 1.74±1.08b 0±0b 5.25±1.05a, b 1.33±0.82b 0.0±0.0c
Colistin (n = 15) 2.86±1.21b 1.62±1.00b 0±0b 1.86±0.79c 1.08±0.69b 0.0±0.0c
Imipenem (n = 15) 7.24±0.19a 5.83±0.68a 3.56±0.98a 6.93±0.24a 5.70±0.66a 2.32±0.71b
Tigecycline (n = 15) 1.91±1.21b 1.43±0.91b 1.24±0.76b 1.36±0.84c 0.96±0.60b 0.89±0.55c
Imipenem + sulbactam (n = 15) 5.05±1.29a, b 2.80±1.15b 1.31±0.80b 2.68±1.10b, c 1.80±1.10b 1.26±0.77b, c
Colistin + sulbactam (n = 15) 3.31±1.09b 1.56±0.96b 1.16±0.71b 2.65±1.05b, c 1.18±0.76b 0.0±0.0c
Tigecycline + sulbactam (n = 15) 2.95±1.25b 1.01±0.64b 0.54±0.54b 2.43±1.15b, c 0.98±0.60b 0.44±0.44c
 Results are shown as the mean ± standard error of the mean. Statistically significant differences between groups are indicated by dif-
ferent superscript letters in the same column (p < 0.05).
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of patients with pneumonia due to carbapenem-resistant 
 A.  baumannii strains. Also, in another experimental 
study, they recommended that colistin monotherapy may 
not be the best option for infections caused by the highly 
resistant strains susceptible only to this antibiotic in vitro. 
A combination of rifampin-imipenem, rifampin-amino-
glycoside or even rifampin-colistin may be more advis-
able  [2] . These studies used the experimental pneumonia 
model where penetration of colistin and other antibiotics 
to the lung is inadequate. Also, in our study bacterial 
clearance of the liver was better than that of the lung with 
all antibiotics. The combination therapy did not have an 
additional effect on the clearance of bacteria from the 
lung. In our very recent clinical study, we compared the 
clinical and microbiological efficacy of colistin and colis-
tin-sulbactam therapy for the treatment of multidrug-re-
sistant  A. baumannii ventilator-associated pneumonia. 
Although the difference was not statistically significant, 
the clinical cure rates and bacteriological clearance rates 
were more successful in the combination group  [30] .
 In this study, colistin and tigecycline had earlier bac-
tericidal activity than sulbactam; at 72 h, colistin and sul-
bactam were the most active agents. Overall, the most ef-
fective therapy in carbapenem-resistant  A. baumannii 
 sepsis was colistin.
 In conclusion, the treatment of life-threatening car-
bapenem-resistant  A. baumannii infections is a serious 
concern. Colistin appears to be the most effective agent 
against serious infections. However, toxicity, the develop-
ment of resistance and the poor lung penetration of colis-
tin lead clinicians to pursue different therapies. Sulbactam 
is a promising agent against carbapenem-resistant  A. bau-
mannii infections, but its single use is not advisable for 
serious infections as resistance may appear during treat-
ment. Despite the results of this study, combination ther-
apy was not superior to monotherapy. Further clinical 
studies are needed in order to prove if sulbactam increas-
es the clinical effectiveness and reduces the mortality 
which also prevents colistin-resistant mutants.
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Chapter 10 
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The major burden of nosocomial infections caused by multi-drug resistant A.baumannii needs 
immediate attention. Several approaches have been purposed including stringent infection control 
regimes, various combinations of antibiotics and development of new vaccines.  
 
In chapter no. 2, we performed molecular characterization of carbapenem resistance genes in 
A.baumannii in which we found 19% out of 188 isolates carried blaOXA-23-like, which was low compared to 
other studies reporting 100%, 33% of isolates carried blaOXA-23-like, and one isolate reporting blaOXA-58-like 
which was first in Turkey. A.baumannii was isolated from patients who were admitted hospital for 
medical conditions and had one or more predisposing factors to A.baumannii infections. As noted in the 
most common underlying condition was corticosteroid therapy (n=51, 24.9%) followed by diabetes 
mellitus (n=42, 20.5%), malignancy (n=33, 16.1%) and chronic obstructive pulmonary disease (COPD) 
(n=31, 15.1%). The most common invasive diagnosis procedure was from urinary catheter (n=152, 
74.1%) followed by central venous catheter (n=117, 57.6%). Of all cases, (n=44, 23.4%) patients 
admitted to ICU of which (n=16, 8.5%) patients had most common reason for admission was respiratory 
disease. This was not surprising as A.baumannii has capability of surviving in ventilation devices in ICU.  
In this study, we found EU Clone I, II and III and was first study to identify EU Clone III, however, EU 
Clone I and II were already been reported by previous studies. 
 
We also compared cost effectiveness of and different typing methods especially for resource limited 
countries. We found PCR-based typing methods are economically, since thermocyclers can be used for 
various PCR based reactions including typing and technically suitable for resource limited laboratories in 
developing countries. Cost of the molecular techniques was calculated in which RAPD-PCR was the most 
economic method, however, PFGE is gold standard but laborious, time consuming and expensive REP-
PCR was also economic. We also found the first sources of A. baumannii isolates were wound/drainage 
and skin and soft-tissue samples, representing 26.3% of all samples. This could be explained by the 
ubiquitous dissemination of A. baumannii in all units from patients with trauma, burns, devices or 
invasive medical procedures such as catheters and drains. 
 
In chapter no. 3, we evaluated various molecular methods in typing A.baumannii clones in which we 
found substantial improvements in genotyping methods that changed the current approaches of 
identification. There has been a major development in bioinformatics tools and molecular techniques 
worldwide. Furthermore, increasing genotypic databases allow quick and easy exchange of data 
between laboratories across to enable comparison and assessment of Acinetobacter surveillance. Every 
genotypic approach has its own benefits and drawbacks. Accordingly, one or more genotypic 
approaches can be used, but this is dependent upon the laboratory setting and the available financial 
support. Ribotyping also has good discriminatory powers in assessing the ACB complex; however, a 
banding patterns complex and libraries of profiles of well-defined strains are required for species 
identification. If a quick analysis is needed then PCR-based methods can be used, however, if the 
outbreak is disseminating to various geographical regions, more robust techniques such as PFGE should 
be used. Although MLST is quick and reliable, it still requires an expensive system to be implemented, 
well-trained staff, quality controlled laboratories, and a large budget for consumables. It is easier to 
implement the MLST and PFGE methods locally, but national or international surveillance needs to 
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standardize its techniques. In resource limited countries; SLST could be another option for provisional 
genotyping, since it is cheaper and faster. In conclusive, PFGE and MLST remain the most widely used 
genotyping methods for the Acinetobacter species.  
 
In chapter no. 4, we studied antimicrobial efficacy of doripenem and its combinations with sulbactam, 
amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant A.baumannii. Due to the 
overuse of carbapenems, many centers have faced the emergence of carbapenem-resistant 
Acinetobacter spp. and the incidence is reported to be over 50%. In our recent study, this rate was 
detected to be 92% in intensive care units with a high crude mortality. Due to the emergence of 
resistance against different classes of commercially available antimicrobials, colistin has been 
reconsidered as a therapeutic option. However, the clinical effectiveness of colistin is still doubtful and 
very low rates have been reported. Although combination therapies may be alternative therapeutic 
options for better clinical efficacy, there are limited data on these therapies.  
 
This study indicated that combination therapies with doripenem were better than doripenem 
monotherapy in terms of bacterial clearance of lung and liver at 48 h. reported that although amikacin 
and imipenem had synergistic effects on experimental multi-resistant A. baumannii pneumonia, the in 
vivo effects of combination therapy were not superior to imipenem monotherapy. However in this 
study, the combination with amikacin had a rapid bactericidal effect at 48 h. we studied antimicrobial 
efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in 
experimental sepsis of carbapenem-resistant A.baumannii.  Amikacin and tigecycline appear to be the 
most effective agents in combination with doripenem. In addition, some experimental infection models 
have shown that imipenem, meropenem or rifampicin combinations with sulbactam are more effective 
than monotherapy.  
 
In chapter no. 5, we studied global epidemiology on colistin resistant A.baumannii, in which we reported 
highest resistance rate from Asia-Pacific followed by Europe, Americas and Africa. Colistin has been as a 
therapeutic option for the treatment of ventilator associated pneumonia caused by drug resistant Gram 
negative organisms. Colistin resistance have been uncommon during 90s, however, the first case was 
reported from Czech Republic in 1999. The Clinical and Laboratory Standards Institute (CLSI) has 
selected an MIC of ≤ 2 μg/ml as susceptible and an MIC of ≥ 4 μg/ml as resistant for colistin.  The clinical 
importance of colistin-resistant strains may be seen in the context of heteroresistance in A. baumannii 
strains and the emergence of colistin-resistant pathogens following treatment of MDR isolates with 
colistin. Furthermore, there is no report of colistin resistance from Northern Europe and Northern Asian 
countries. There are reports from almost all Mediterranean countries like Turkey, Greece, Italy, Spain, 
Portugal, Egypt, Algeria and Tunisia. Although colistin resistance is increasing continuously, clinicians 
should carefully detect risk factors for its cause. Colistin resistance can be suppressed through reversing 
efflux pump activity by using EPIs such as cyanide 3-cholophenylhydrazone (CCCP), phenyl-arginine-β-
naphthylamide (PAβN), and 1-(1-naphthylmethyl)-piperazine (NMP) could be used. 
 
In chapter no. 6, we discussed various issues required to establish molecular microbiology facility in 
developing countries and the role of molecular techniques in clinical microbiology and epidemiology. 
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 Molecular techniques in high-quality clinical microbiological laboratories are routinely used to make 
clinical decisions, monitoring patients, effectiveness of therapeutic regimes and identifying potential 
resistant strains that may impact a long term treatment program. We also reviewed various molecular 
techniques required to function a molecular microbiology laboratory. Furthermore, we discussed newer 
technologies such as Real-time droplet PCR, Mass spectrometry, Nucleic acid sequence analysis, 
Microbial volatile organic compounds, Raman spectroscopic analysis and Nano-particles. We reviewed 
various issues on laboratory management, networking system, biosafety, risk assessment, accreditation, 
design, practice and personnel requirements.  
 
In chapter no. 7, we analyzed challenges of ICU-acquired Infections and A. baumannii in developing 
countries. We investigated the prevalence of infection and mortality rates are higher in countries with 
limited resources associated with the quality of care. The main problems in developing countries are 
understaffing, poor infrastructure in ICUs and overcrowding. Although it is difficult to solve some 
problems associated with financial hardship in developing countries most solutions are simple and not 
resource- demanding. Infection control strategies; hand hygiene, rational antibiotic utilization, 
continuous educations and performance feedback demonstrated significant reduction of the infection 
rates in these countries. A.baumannii is common cause of nosocomial infections worldwide. Risk factors 
of Acinetobacter infection is already known and acute vaccination and antibody based immune 
therapies for patients at the risk of these infections looks promising to prevent infections and improve 
outcomes. 
 
In chapter no. 8, we investigated clonal relationship between European clones I, II and III with local 
clones collected in ten centers across Turkey and one center in Azerbaijan. Furthermore, we also 
assessed carbapenem resistance genes. We found various plasmid mediated carbapenem resistance 
genes blaOXA-23-like gene present in 67% of isolates, blaOXA-24-like gene present in 4.5% of isolates and blaOXA-
58-like present in 6.2% isolates. The blaOXA-24-like gene was first identified in Izmir in the far western 
region of Turkey in 2013. In this study, the rarely identified blaOXA-24-like gene in Turkey and for the 
first time from Azerbaijan has been reported. Interestingly, in this study, this gene was identified again 
from Izmir and Erzurum, in the eastern region of Turkey. Several clusters were identified, in which F 
cluster was commonly found in Northern and Eastern parts of Turkey. There has been an increase in the 
occurrence of blaOXA-58-like genes nowadays throughout Turkey, since earlier studies reported less 
prevalence; in this study, we observed that 6.2 % of isolates carried blaOXA-58-like genes.EU clone 1 
was grouped to J cluster with 3 isolates and EU clone 2 was grouped to U cluster with 15 isolates found 
mainly in Kayseri, overall 16 % of all isolates belonged to European clones I and II.  
 
In chapter no. 9, we studied the efficacy of sulbactam and its combination with imipenem, colistin and 
tigecycline in an experimental model of carbapenem-resistant A. baumannii sepsis in which we 
investigated the additional effect of sulbactam on monotherapy with colistin, tigecycline and imipenem. 
In which imipenem did not decrease the bacterial load, but the other antibiotics showed significant 
bactericidal activity compared with the control group, and the combination of imipenem with sulbactam 
decreased the bacterial load in lung and liver. However, the addition of sulbactam to colistin and 
80
tigecycline had no significant effect on bacterial counts. Only the addition of sulbactam to imipenem 
showed better bactericidal activity compared to imipenem alone.  
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